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ABSTRACT OF THE DISSERTATION
Generating High Purity Embryonic Stem Cell-derived Cell Populations for
Transplantation Following Spinal Cord Injury
by
Dylan Alexander McCreedy
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2013
Professor Shelly E. Sakiyama-Elbert, Chair

Embryonic stem cells hold great potential for cell replacement strategies in the
central nervous system.

Pre-differentiation into various neural cell types can help

generate tissue-specific cell populations that can replace cells and tissue lost due to do
injury or disease. A small number of undifferentiated pluripotent stem cells persist in
most transplant populations even after pre-differentiation.

Given the right

environment, i.e. biomaterial scaffolds, these cells can lead to tumor formation thereby
eliminating any potential therapeutic benefit.

This dissertation focused on the

development of high purity embryonic stem cell-derived cell populations devoid of
pluripotent stem cells for transplantation into the central nervous system, in particular
the injured spinal cord.

In the first study, transgenic expression of the puromycin

resistance enzyme, puromycin N-acetyltransferase, is driven by the gene regulatory
elements of the progenitor motor neuron associated transcription factor Olig2.
Selection by puromycin exposure resulted in an enriched population of progenitor
motor neurons, as well as recent progeny of progenitor motor neurons. Furthermore,
undifferentiated stem cells were removed by puromycin selection. The efficacy of these
x

enriched populations was evaluated in tissue engineered fibrin scaffolds containing a
heparin-based delivery system for controlled delivery of two growth factor
combinations.

Greater differentiation into oligodendrocytes in vitro was observed in

selected cell groups compared to unselected controls in fibrin scaffolds delivery
neurotrophin-3 and glial derived neurotrophic factor. Enriched progenitor motor
neurons survived and differentiated into oligodendrocytes, astrocytes and motoneurons
in a two week sub-acute dorsal hemisection model of spinal cord injury. Encapsulating
the transplant population in the tissue engineered fibrin scaffold with growth factors did
not enhance proliferation or survival suggesting that tumorgenic cell populations were
not present.

In the final study, high purity mature cholinergic motoneurons were

generated by driving puromycin resistance under control of two highly conserved
enhancers for the motoneuron transcription factor Hb9. Puromycin selection resulted
in a uniform group of post-mitotic immature motoneurons.

Purity was observed

through maturation and no proliferating glia were observed at any time point. Selected
motoneurons maintained appropriate electrophysiological characteristics. Through this
work, antibiotic selection appears to be a suitable method for generating high purity EScell derived neural populations.

xi

Chapter 1
Introduction*
1.1 Overview
The goal of this dissertation was the development of high-purity embryonic
stem (ES) cell-derived cell populations for use in spinal cord injury (SCI).
Tumorgenicity is a major concern when using pluripotent ES cells for therapeutic
applications within the body. Pre-differentiation of ES cells significantly reduces the
potential for tumor formation following transplantation, however, pluripotent
undifferentiated ES cells can still persist. Recent developments in biomaterial scaffolds
and growth factor delivery have been shown to improve the survival, differentiation,
and maturation of differentiation ES cells transplanted after SCI. Unfortunately,
creating a more permissive environment can also promote the survival and proliferation
of the undifferentiated ES cells that persist in the transplant population. The objective
of the following research was to develop high-purity ES cell-derived transplant
populations devoid of pluripotent ES cells to realize the full therapeutic potential
without the downfall of potential tumor formation.
The first goal of this thesis was to develop a uniform population of progenitor
cells for therapeutic application after SCI. Differentiation of ES cells usually suffers
from low efficiency resulting in a heterogeneous population of cells. Subsequent
purification is therefore necessary to removed undesired cell types. Progenitor cell
*Portions of this work were published in McCreedy, DA and SE Sakiyama-Elbert. Neurosci Lett. 2012
Jun 25;519(2):115-21 and were reprinted with permission of the publisher.
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populations have greater survival rates following transplantation into the injured spinal
cord than terminally differentiated mature cell types and may represent an ideal
therapeutic population. Progenitor motor neurons (pMNs) were targeted due to the
well-studied development of this cell type and the ability to differentiate into
motoneurons and oligodendrocytes, two potential therapeutic cell types for repair after
SCI.
Determining the survival and differentiation of high purity pMNs within fibrin
scaffolds contained growth factors and a heparin binding drug delivery system (HBDS)
was the second objective of this dissertation. Fibrin scaffolds containing growth factors
and the HBDS have been shown to improve the differentiation of a heterogeneous
population of ES neural progenitor cells (ESNPCs) in vitro and promote the survival of
the same cell population in vivo (Willerth et al., 2008, Johnson et al., 2010a). Fibrin
scaffolds containing growth factors, however, may have promoted over-proliferation of
undesired cell types. The effect of these components on survival and differentiation of
high purity pMNs was examined after a two-week culture period in vitro. High purity
pMNs were then transplanted within fibrin scaffolds into a sub-acute rodent model of
SCI for two weeks to assess survival and differentiation in vivo.
The third objective of this thesis focused on the development of a high purity
culture of ES cell-derived motoneurons. While pMNs show greater survival, they are
also multi-potent and can give rise to motoneurons and glia. Glia can quickly proliferate
and over-take in vitro cultures while the number of post-mitotic motoneurons remains
constant. This greatly limits the number of studies that can be conducted using ES-cell
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derived motoneurons. Isolating a single cell type also has advantages in determining
mechanism of recovery following transplantation into the injured cord.
The overall objective of this work is to provide a simple, inexpensive,
reproducible, and effective method for high purity ES-cell derived cell populations.
While the initial intended purpose is repair of SCI, these populations have potential in
toxicology screening, developmental biology, stem cell technologies, and many other
fields of science. The following introduction will discuss the pathophysiology of SCI
and subsequent attempts to repair the injured cord using cell transplants, in particular
the use of ES-cell derived populations, and bioengineered combination therapies
involving cell transplantation.

1.2 Spinal cord injury
SCI is a debilitating event resulting in disrupted motor and sensory pathways.
Approximately 12,400 new cases occur annually in the U.S. adding to over 250,000
persons already living with SCI (Devivo, 2012, National Spinal Cord Injury Statistical,
2013). The main cause of SCI in the U.S. is motor vehicle-associated accidents followed
by falls, violence, and sports accidents. The average lifetime cost is $69,204 per year,
with more severe injuries resulting in higher medical costs. SCI injury significantly
reduces life expectancy, primarily through increased susceptibility to pneumonia and
infection related complications, such as septicemia. The debilitating nature of SCI
injury can also reduce productivity. The employment rate of persons with SCI one year
following injury is 11.7% compared to 57.1% at the time of injury. Promoting recovery
following SCI can reduce total lifetime costs and enhance the overall quality of life.
3

Scientific research dedicated to improving regeneration following SCI has made
significant strides in the past decade. The main focus of this research has been directed
towards understanding the cellular and molecular events that follow SCI and the
development of corresponding therapeutic strategies.
Initial mechanical trauma during SCI severs axons, damages vasculature, and
promotes necrotic cell death (McDonald and Sadowsky, 2002, Thuret et al., 2006). The
ensuing vascular, cellular, and inflammatory events propagate cell death in a secondary
phase of injury that expands the lesion site significantly. Infiltrating Schwann cells,
fibroblasts, and glia progenitors along with activated microglia and astrocytes form an
interwoven cellular layer between the injured and naïve tissue (Bruce et al., 2000, Guest
et al., 2005, Thuret et al., 2006). Many cells within this glial scar express chondroitin
sulfate proteoglycans (CSPGs) that inhibit cell migration and axon regeneration (Jones
et al., 2003). In cases of severe SCI, the necrotic tissue inside of the scar forms a cystic
cavity lacking any growth promoting substrates. Regeneration following SCI is severely
limited, prompting many therapeutic strategies including cell replacement therapies. The
catastrophic events that advance cell death and tissue destruction following SCI are
reviewed below.

1.2.1 Secondary Degeneration in Spinal Cord Injury
Initial mechanical trauma leads to several mechanisms of secondary
degeneration in SCI. Due to the complex nature of SCI, the causality of each
individual mechanism on cell death and tissue destruction can be difficult to discern. In
many cases, the events are overlapping and intertwined. Some of the main events that
4

lead to cell death and expansion of the injury site following traumatic insult are reviewed
below.

Vascular Mechanisms

Disruption of spinal cord blood flow is a critical factor in

the severity of SCI and the resulting cell death. Vessel damage occurs instantaneously
during SCI leading to drastic changes in the vascular architecture. Hemorrhages are
observed in the grey matter within 15 minutes post-SCI in human and rodents (Noble
and Wrathall, 1989, Tator and Koyanagi, 1997). Hemorrhaging extends into the white
matter at 24 hours and 1 week post-injury. At the epicenter of the injury, this is often
accompanied by necrotic tissue and cavity formation in the grey matter with swollen
axons in the white matter (Noble and Wrathall, 1989). Ischemia and edema are also
observed following damage to the spinal cord vasculature in SCI (Koyanagi et al., 1989,
Tator and Fehlings, 1991, Tator and Koyanagi, 1997, Rowland et al., 2008). In a cervical
clip compression model of SCI in adult rats, reduced spinal cord blood flow correlated
with injury severity and loss of motor function (Fehlings et al., 1989). Blood vessels
were shown to be completely destroyed at the lesion epicenter 2 days post-SCI in
rodents (Casella et al., 2002). In this study, neuronal loss accompanied vascular
destruction. Many strategies have been developed to limit swelling and ischemia
following SCI (O'Carroll et al., 2008, Saadoun et al., 2008, Fassbender et al., 2011). In a
recent study in rats, preservation of axons and reduced apoptosis was achieved via
expression of vascular endothelial growth factor to enhance angiogenesis (Liu et al.,
2010). These studies demonstrate the fragile and unstable nature of the spinal cord
microvasculature and its profound effect on cell death following SCI.
5

Ionic and Excitotoxic Mechanisms

Ionic imbalance is another mechanism for

progressive cell death following SCI. Failure of ATP-dependent Na+ and K+ ion
exchange as well as persistently activated voltage gated Na+ channels can promote
depolarization following SCI (Faden et al., 1987). High intracellular [Na+] can reverse
the Na+-Ca+ exchanger leading to accumulation of Ca+ and cell death via secondary
messenger cascades (Stys et al., 1992, Park et al., 2004). To this end, Na+ channel
blockers have been shown to promote white matter sparing and functional recovery
following SCI (Schwartz and Fehlings, 2001, Hains et al., 2004). Glutamate
excitotoxicity can also play a large role in cell death following SCI. (Wrathall et al.,
1996). Failure to maintain the Na+ gradient can inhibit Na+ glutamate exchange leading
to glutamate accumulation (Li and Stys, 2001). Glutamate excitotoxicity is exerted
through NMDA receptors in the grey matter leading influx of Ca+ ions (MacDermott et
al., 1986). AMPA receptors have been implicated for white matter injury (Agrawal and
Fehlings, 1997, Park et al., 2004). The careful maintenance of ion concentrations can be
drastically disrupted following SCI with several downstream consequences culminating
in cell death.

Immune Reaction Mechanisms

Inflammation plays a major role in the secondary

phase of cell death following SCI. The initial mechanical insult initiates cytokine
expression in resident spinal cord cells leading to leukocyte recruitment. Expression of
interleukin-1beta (IL-1β) and tumor necrosis factor-alpha (TNFα) is detected by 15
minutes post-injury (Pineau and Lacroix, 2007). In mice, IL-1β mRNA peaks at 12
hours following spinal cord contusion injury. Astrocytes and microglia are mainly
6

responsible for IL-1β expression whereas TNFα is secreted by neurons and
oligodendrocytes as well. Peak expression for TNFα corresponds to 1 hour post-injury
and again at 28 days post-injury.
Neutrophils are the first peripheral immune responders to lesion site and
infiltrate within 2-3 hours after injury. The number of invading neutrophils peaks
around 24 hours (Carlson et al., 1998, Fleming et al., 2006, Donnelly and Popovich,
2008). Neutrophils release proteases and reactive oxygen species leading to non-specific
degradation of injured tissue as well as surrounding uninjured tissue and cells (Taoka
and Okajima, 2000). In rodents, blood-derived macrophages and activated microglia
enter 3-4 days following injury (Stirling and Yong, 2008). Macrophages/microglia
phagocytose apoptotic neutrophils, necrotic tissue and myelin debris. Similar to
neutrophils, macrophages release proteases and reactive oxygen species resulting in nonspecific cell death of uninjured cells (Alexander and Popovich, 2009). T cell and B cell
recruitment during adaptive immunity also impacts recovery following SCI, however,
many conflicting results exists on the role of these cells in regeneration (David et al.,
2012, Wu et al., 2012, Laliberte and Fehlings, 2013). Together, innate and adaptive
immunity contribute to the rapid expansion of the injury site and progressive loss of
function. Despite the grim outlook following SCI cast by the overlapping and
seemingly endless causes of cell death, endogenous cell activation does occur following
SCI. The work on these cell types is reviewed in the next section.

7

1.2.2 Endogenous Spinal Cord Stem Cells following SCI
Recovery of function in lower vertebrates is dependent on proliferation of
progenitor cells in the central canal to repopulate the spinal cord. In zebra fish, Olig2+
cells in the central canal give rise to new motoneurons following SCI (Dias et al., 2012).
In mammals, proliferation of progenitor cells at the central canal increases significantly
after high thoracic transaction of the dorsal finiculus (Johansson et al., 1999). Meletis
and colleagues performed an elegant study to determine the source of progenitor cells
from the central canal. Using conditional reporter mice expressing cre recombinase
under the nestin reporter, ependymal cells lining the central canal were identified as
multi-potent progenitors giving rise to oligodendrocytes and astrocytes following SCI
(Meletis et al., 2008). While a small portion of these cells can repopulate lost cell
populations, many remain undifferentiated or contribute to glia scar formation and
expression of CSPGs. No neuronal differentiation from endogenous stem cells has
been observed in rodent or non-human primate SCI (Yang et al., 2006, McDonough
and Martinez-Cerdeno, 2012). Beyond stem cells, endogenous NG2+ glial progenitors
increase proliferation after SCI and give rise to astrocytes, oligodendrocytes, and
microglia (Horner et al., 2000, Zai and Wrathall, 2005).
The increase in proliferation following injury suggests that repopulation is
possible following SCI. Unfortunately, neuronal differentiation is not observed and
many of the new cells contribute to scar formation. While remyelination is observed in
some studies, it is unclear to what extent this occurs. As a result, cell transplantation
has become a viable therapeutic to replace lost populations. In the next section, we will
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review the main cell types used for replacement, and demonstrate the therapeutic value
of each.

1.3 Cell Replacement Strategies
A wide variety of cell types have been examined for their therapeutic potential
towards repair of the injured spinal cord. Schwann cells and olfactory ensheating glia
were originally investigated due to their known potential for regeneration in nervous
system injuries. Other cell types, including bone marrow stromal cells, have been
studied based on the ease of deriving autologous populations thereby avoiding implant
rejection. More convincing studies of late have sought to utilize cells common to the
spinal cord, such as neural progenitor cells, with known functions in the central nervous
system (CNS). With the exception of autologous cells, all transplants require immune
suppression to prevent rejection. This commonly occurs through administration of
cyclosporin A, however, the therapeutic effect of cyclosporin A alone has been
previously demonstrated (McMahon et al., 2009). Carefully controlled studies are
necessary to discriminate the effects of cell transplants from cyclosporin A. In this
section we will review the main cell types used for SCI repair.

1.3.1 Schwann Cells
Schwann cells are the myelinating glia of the peripheral nervous system (PNS).
During injury to the PNS, Schwann cells help phagocytose myelin debris and cooperate
with fibroblasts to form bands of Bungner that promote regeneration of ascending and
descending nerve axons (Parrinello et al., 2010). Schwann cells express a variety of
9

growth factors in peripheral nerve injury to promote axon regeneration including nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF), and ciliary
neurotrophic factor (Heumann et al., 1987, Friedman et al., 1992, Meyer et al., 1992).
Following SCI, Schwann cells infiltrate into the lesion center and occasionally
remyelinate spared axons in the peripheral white matter (Bresnahan et al., 1976, Bunge
et al., 1994, Beattie et al., 1997, Bruce et al., 2000). Schwann cells can be harvested from
peripheral nerves and expanded in vitro (Morrissey et al., 1991). Furthermore,
autologous Schwann cells from the same SCI patient can be taken to reduce immune
rejection (Bunge, 2002). In complete transaction models of SCI in rats, transplanted
Schwann cells contained within polyacrylonitrile/polyvinylchloride (PAN/PVC)
conduits improved regeneration of propriospinal neurons into the conduit (Xu et al.,
1995). In a follow up study, regeneration was observed from both the rostral and
caudal ends of the severed spinal cord (Xu et al., 1997). Significant recovery of function
by Schwann cell transplantation without additional factors used in combination,
however, has only been reported in a few studies (Takami et al., 2002, Barakat et al.,
2005, Schaal et al., 2007). Combination therapies involving Schwann cells will be
reviewed in the final section of the introduction.
Schwann cells derived from non-nerve autologous sources have shown promise
for repair following SCI. Skin-derived precursors (SKP), a potential neural crest stem
cell analogue, can be expanded from mammalian skin and retain the ability to
differentiate into Schwann cells (Fernandes et al., 2004, McKenzie et al., 2006). When
transplanted in a contusion model of SCI, SKP-derived Schwann cells increase the
number of serotinergic fibers at the injury site and improve remyelination both at the
10

injury site and in the spared rim of white matter (Biernaskie et al., 2007). Small but
significant improvements were observed similar to those seen with nerve-derived
Schwann cells. Overall, Schwann cells have yet to live up to their potential for
regeneration observed following peripheral nerve injury. Regardless, human clinical
trials are proceeding to examine the efficacy of this cell type for clinical repair of SCI
(Saberi et al., 2008). Properly conducted clinical trials may elucidate the role of
autologous Schwann cell transplantation in repair of SCI.

1.3.2 Olfactory Ensheathing Glia
Olfactory ensheathing glia, also known as olfactory ensheathing cells (OECs),
help peripheral olfactory axons migrate into the central nervous system olfactory bulb
following transection. The ability to promote regeneration into the central nervous
system is maintained through life (Doucette, 1990, 1991). Similarly, OECs have been
shown to promote regeneration of axotomized dorsal root axons into the spinal cord
(Ramon-Cueto and Nieto-Sampedro, 1994). Mixed OEC cultures transplanted into a
cervical lateral hemisection injury appeared to induce regeneration of corticospinal tract
axons by creating a cellular bridge across the lesion (Li et al., 1997). OEC myelination
of axons was observed; however, behavioral outcome was not reported. Transplantation
of OECs into a thoracic complete transaction injury led to improved motor function
and elongation of serotinergic axons (Ramon-Cueto et al., 2000). In a later study,
recovery of hindlimb function and regeneration of serotinergic axons up to the caudal
stump were observed following OEG transplantation and treadmill rehabilitation after
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complete thoracic transaction SCI in rats. OEG transplantation alone, however, was
not able to elicit a similar response.
When compared to Schwann cells, OECs exhibited a lesser impact on recovery
of function following thoracic contusion injury (Takami et al., 2002, Barakat et al.,
2005). Increased fiber regeneration, however, was observed following transplantation
of OECs into the transected thoracic spinal cord. Transplantation of olfactory nasal
mucosa, a common source of OECs, has been shown to improve recovery of motor
function following a thoracic full transection SCI (Lu et al., 2001, Lu et al., 2002).
Independent verification of these results, however, failed to replicate similar recovery of
locomotion (Steward et al., 2006). While OECs do appear to demonstrate therapeutic
potential, it is limited and may be better suited for guiding axons between the PNS-CNS
interface. The lack of easily attainable autologous sources may limit the clinical
translation of OECs.

1.3.3 Bone Marrow Stromal Cells
The therapeutic potential of bone marrow stromal cells (BMSCs) for repair after
SCI has been heavily debated. Much of this stems from whether or not BMSCs retain
the ability for differentiation into the neural lineage. Lu and colleagues demonstrated
that expression of neural markers in BMSCs in vitro was not sustained following
transplantation into the injured cord (Lu et al., 2005).

Furthermore, neurally induced

BMSCs did not differ from naïve BMSCs 1 month post-grafting. BMSCs do, however,
fill the lesion cavity and secrete growth factors that may improve regeneration indirectly.
In some studies, BMSCs were shown to promote improved functional recovery (Chopp
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et al., 2000, Hofstetter et al., 2002). Despite early promise, behavioral data and histology
following transplantation of BMSCs into the injured cord is variable (Tetzlaff et al.,
2011). The ease of obtaining autologous BMSCs has ushered their use into the clinical
setting, though this may be somewhat premature (Harrop et al., 2012). BMSCs do
appear to help reduce cystic cavity formation and secrete growth factors that may play a
role in neuroprotection and plasticity following SCI. No further evidence on any
specific neural functionality, including neural differentiation and synaptic connectivity
with host neurons, has been demonstrated to date.

1.3.4 Neural Stem Cells
Replacing lost spinal cord cell populations with phenotypically similar cell types
has great potential for recovery of function in SCI. Neural stem/progenitor cells
(NSCs) and fetal spinal cord tissue represent two pre-clinical sources of neural cells
including neurons, astrocytes, and oligodendrocytes. NSCs can be amplified from CNS
tissue in the presence of fibroblast growth factor-2 and epidermal growth factor to form
neurospheres (Reynolds and Weiss, 1992, Mothe et al., 2008). More specific neuronal
restricted precursors (NRPs) and glial restricted precursors (GRPs) can be obtained
from fetal spinal cord tissue by immunopanning for the cell surface markers PS-NCAM
or A2B5 respectively (Cao et al., 2002, Cao et al., 2005).
Engraftment of fetal spinal cord tissue following SCI typically fills the spinal
cord lesion and functional connections are established between host and graft neurons
in both rodent and feline models of SCI (Houle and Reier, 1989, Reier et al., 1992).
Recently, rat spinal cord fetal tissue has been used to demonstrate long distance axon
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extension from engrafted neurons into the host tissue following complete thoracic
transection (Lu et al., 2012). Fetal spinal cord tissue contains many interneurons that
can relay ascending and descending signals through the injury site. Despite the often
positive observations, the lack of a suitable equivalent human tissue source has hindered
the development of this strategy.
NSCs can be generated from both embryonic and adult CNS tissues. In
addition, different CNS regions can give rise to NSCs including the subventricular zone
(SVZ) of the striatum and the periventricular zone of the spinal cord (Reynolds and
Weiss, 1992, Mothe et al., 2008). Transplantation of rat NSCs from the embryonic
cortex or adult subventricular zone following sub-acute contusive injury resulted in
primarily astrocyte differentiation with no oligodendrocytes or neurons (Cao et al.,
2001). Sub-acute engraftment of adult mouse NSCs from the SVZ into compressive
spinal cord injury, however, produced mainly oligodendrocyte differentiation, enhanced
remyelination, and improved motor function as assessed by the Beattie-BassoBresnahan (BBB) locomotor scale (Karimi-Abdolrezaee et al., 2006, Parr et al., 2008).
Human NSCs from fetal brain have also been shown to promote locomotor recovery
(Cummings et al., 2005). In this study, human NSCs differentiated into neurons and
formed contacts with host neurons in a mouse contusive SCI model. Differentiation
into oligodendrocytes and subsequent myelination was also observed. In some cases,
increased sensitivity to noxious stimuli or allodynia was observed, and this may limit the
efficacy of NSC-based therapies (Hofstetter et al., 2005, Macias et al., 2006). Some of
the variability observed in response to NSC transplantation may be explained by age,
species, and region specific differences in NSCs, along with the variability of in vitro
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culture conditions of NSCs. Immortalized human NSC lines may ultimately provide a
consistent source for clinical translation of NSC-based therapeutic strategies; however,
these are not autologous and pose the risk of immune rejection.
NRP and GRP populations provide more restricted lineage cells for SCI repair
compared to NSCs. NRPs, unfortunately, show poor survival and differentiation into
neurons following transplantation into the contused spinal cord (Cao et al., 2002).
Similarly, GRPs are limited by predominant differentiation into astrocytes within the
injured cord (Han et al., 2004, Hill et al., 2004, Enzmann et al., 2005, Tetzlaff et al.,
2011). Mixtures of NRPs and GRPs can promote recovery of function, however, the
advantage of these cells over NSCs is unclear (Mitsui et al., 2005, Neuhuber et al., 2008).
Furthermore, the ethical limitations of suitable human fetal tissue render NRP/GRP
therapies unlikely in the near future.

1.3.5 Embryonic Stem Cell-derived Neural Populations
The idea of replacing damaged neural tissue after SCI has prompted
investigation into ES cell-derived neural cells. ES cells can be expanded indefinitely and
give rise to all tissues of the body. McDonald and colleagues first demonstrated the
viability of neurally-induced ES cells transplanted in contusive rat SCI (McDonald et al.,
1999). Cells survived and differentiated into astrocytes, oligodendrocytes, and neurons.
Partial recovery of function was demonstrated by BBB and gait analysis. In a follow-up
study, ES cell-derived oligodendrocytes were shown to myelinate demyelinated axons
suggesting a potential mechanism for recovery (Liu et al., 2000). In addition, authors
manipulated the in vitro culture conditions to create oligospheres, which are cellular
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aggregates highly enriched for oligodendrocytes. ES cells induced into the neural lineage
have also been shown to improve both spontaneous and evoked pain behaviors in
spinal cord injured mice (Hendricks et al., 2006).
High purity human ES cell-derived oligodendrocyte progenitor cells (OPCs)
have been generated for repair and remyelination. Following contusive thoracic SCI,
sub-acute transplantation of OPCs lead to greater myelination of spared axons and
increased motor function (Keirstead et al., 2005). Treatment of chronic SCI with OPCs
had no effect on remyelination and recovery. Transplantation of human OPCs into a
cervical SCI improved tissue sparing and motor function while reducing cavitation
(Sharp et al., 2010). Acute transplantation of human OPCs following contusive SCI
promoted recovery of sensory pathways as shown by increased somatosensory evoked
potential amplitudes and reduced latencies (All et al., 2012). Murine OPCs have also
been demonstrated to improve remyelination and motor function following a cervical
X-ray irradiation model of SCI (Sun et al., 2013).
Recently, human ES-derived OPCs and motoneuron progenitors (MPs) were
compared following transplantation into a complete thoracic SCI (Erceg et al., 2010).
Both groups differentiated into oligodendrocytes, neurons, and astrocytes. In addition,
both groups improved functional recovery despite poor survival (<1%). In this study,
poor neuronal differentiation of MPs was observed in the spinal cord. A protocol for
high purity human ES-derived MPs has been developed by the Keirstead laboratory and
was shown to enhance neuronal survival and recovery of functional following cervical
SCI through neurotrophic and cell signaling mechanisms (Rossi et al., 2010). Murine
ES cell-derived motoneurons have been shown to survive and extend axons out into
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peripheral nerve following transplantation in a rodent model of amyotrophic lateral
sclerosis (ALS) (Harper et al., 2004, Deshpande et al., 2006). Similar results have yet to
be achieved following SCI.
The ethical concerns over the use of human ES cells have prompted
investigation into the therapeutic potential of human induced pluripotent stem cells
(hiPSCs) for repair after SCI. Following neural induction of human ES cells,
dissociation in the presence of media hormone mix generated ES cell-derived
neurospheres (Kumagai et al., 2009). Similar steps can be taken to form hiPSC
neurospheres (hiPSC-NS). Sub-acute transplantation of hiPSC-NS into the contused
thoracic spinal resulted in differentiation of cells mainly into neurons and astrocytes,
with a few oligodendrocytes (Nori et al., 2011). Enhanced angiogenesis and tissue
sparing was observed. Grafted cells appeared to make synaptic connections with host
neurons. Locomotor recovery as shown by the Basso Mouse Scale and
electrophysiology was significantly improved in animals receiving hiPSC-NS transplants.
In a later study by the same group, functional recovery was also shown following
transplantation of hiPSC-NS into a common marmoset SCI (Kobayashi et al., 2012).
Neuroepithelial-like stem (NES) cells can also be obtained form hiPSCs and give rise to
multiple neural lineages (Falk et al., 2012). Sub-acute grafting of hiPSC-NES cells
enhanced functional recovery following SCI in immunodeficient mice (Fujimoto et al.,
2012). Neural differentiation of hiPSC-NES cells was observed and was associated
with neuronal sparing. While few phenotype specific functions (i.e. myelination by
oligodendrocytes) are currently observed in studies utilizing hiPSCs, the demonstrated
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behavioral benefits suggest great potential for hiPSCs as a cell therapy for repair
following SCI.

1.4 Embryonic Stem Cells
ES cells give rise to all somatic cell types and have demonstrated immense value
as a tool for studying development and as a therapeutic agent. Martin Evans and
Matthew Kaufman first cultured cells from the inner cell mass of late mouse blastocysts
in media conditioned by teratocarcinoma stem cells (Evans and Kaufman, 1981). When
injected subcutaneously, these cells formed teratocarinomas containing all three germ
layers thus demonstrating pluripotency. The term “embryonic stem cell” was coined by
Gail Martin shortly afterward who independently demonstrated similar results (Martin,
1981). The growth of mouse ES cells required co-culture on mytomycin-C inactivated
fibroblasts feeder layers with media conditioned by teratocarcinomas to maintain their
pluripotent states. The use of media conditioned by buffalo rat liver cells containing
differentiation inhibiting activity (DIA) eliminated the need for fibroblasts feeder layers
(Smith et al., 1988). DIA was later replaced by leukemia inhibitory factor (LIF)
(Williams et al., 1988).
Thomson and colleagues first derived non-human primate ES-cells from Rhesus
monkeys in 1995 (Thomson et al., 1995). Primate ES-cells maintained pluripotency
when cultured on irradiated mouse embryonic fibroblast feeder layers in the presence of
LIF. Unlike mouse ES cells, primate ES cells fail to survive in the absence of feeder
layers. Thomson later derived human ES-cells, bringing ES cell-derived therapeutics
closer to the clinical setting (Thomson et al., 1998). Much controversy exists over the
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use of human ES cells. Recent advances in epigenetics have demonstrated reversion of
somatic cells, typically fibroblasts, back to a stem cell state via the expression of genes
associated with pluripotency including Oct3/4, Sox2, c-Myc, and Klf4 (Takahashi and
Yamanaka, 2006). These aptly named induced pluripotent stem cells (iPSCs) can
generate cells from all three germ layers and may provide a suitable and ethical
replacement for human ES cells. Generating iPSCs from patient skin cells can allow for
autologous cell transplants thereby reducing immune rejection. The following section
reviews the differentiation of ES cells and iPSCs into the neural lineage including
derivation of specific neuronal subtypes.

1.4.1 Neural Induction of ES Cells
Neural differentiation of ES cells can be achieved by aggregating ES cells in the
absence of LIF or other differentiation inhibitors. Multi-cellular aggregates of ES cells,
or embryoid bodies (EBs), mimic developmental events in the embryo and start a
default neural differentiation program in ES cells (Hemmati-Brivanlou and Melton,
1997). Work by the Gottlieb laboratory has demonstrated efficient differentiation of
mouse ES (mES) cells in EBs into neural progenitors through exposure to retinoic acid
(RA) (Bain et al., 1995). RA induced mES cells were shown to differentiate into
oligodendrocytes, astrocytes, inhibitory GABAergic interneurons, and less frequently
into excitatory and cholinergic neurons (Fraichard et al., 1995, Strubing et al., 1995).
Increasing RA concentration was shown to further caudalize mES cells from a
hindbrain to spinal cord cell fate (Okada et al., 2004). RA concentration also influences
the expression of various progenitor, neuronal, and glial markers. Neural differentiation
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with RA has also been shown in human ES (hES) cells (Schuldiner et al., 2000,
Schuldiner et al., 2001). Highly efficient neural induction of hES cells and hiPSCs has
been shown following dual exposure of the bone morphogenic protein inhibitor,
Noggin, and the activin/nodal inhibitor, SB431542 (Chambers et al., 2009). This dual
SMAD inhibition protocol gives rise to neural crest and CNS progenitors, with the
latter showing subsequent differentiation into motoneurons and dopaminergic neurons.
Neural induction by SB431542 was demonstrated to impose a caudal positional identity
in the resulting neural progenitors (Patani et al., 2009). Efficient induction into general
neural progenitor phenotypes can be accomplished by exposure to developmental
signals including retinoic acid or by manipulating signaling pathways common to
development.

1.4.2 Embryonic Stem Cell-derived Neuronal Subtypes
Cues from developmental biology have often guided the directed differentiation
of ES cells into specific neuronal subtypes. Sonic hedgehog (Shh) and fibroblast growth
factor 8 (FGF-8) have been shown to induce dopaminergic differentiation in the
forebrain and midbrain (Ye et al., 1998). Reproducing Shh and FGF-8 signaling in vitro
promoted differentiation of mES and hES cells into dopaminergic neurons (Lee et al.,
2000, Perrier et al., 2004, Yang et al., 2008). Induction protocols for the differentiation
of cortical neurons (Gaspard et al., 2009), cerebellar neurons (Salero and Hatten, 2007),
dorsal interneurons (Murashov et al., 2005), retinal rod and cone neurons (Osakada et
al., 2008), and peripheral neurons (Lee et al., 2007) from ES cells have been developed,
though not all protocols mimic developmental events. The use of chemically defined
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components in published induction protocols is critical to the clinical translation of
therapeutic ES cell-derived cultures. Divergent induction protocols for the same cell
type often result from the use of poorly defined reagents or factors secreted by cocultured cells types, such as stromal cells (Erceg et al., 2009). Consistency in
differentiation protocols can significantly enhance consensus between studies using ES
cell-derived populations.

1.4.3 Embryonic Stem Cell-derived Motoneurons
The differentiation of ES cell-derived motoneurons has been highly consistent
over the past decade. Motoneurons differentiate from a distinct population of cells in
the ventral neural tube called progenitor motoneurons (pMNs) (Dessaud et al., 2008).
The pMN domain forms in response to RA released from nearby somites and Shh
released by the notochord and floorplate cells. While differences in the initial neural
induction of ES cells exists (RA vs. dual SMAD inhibition), published induction
protocols rely on Shh signaling to induce differentiation into motoneurons as originally
published for mES cells by the Jessell group (Wichterle et al., 2002). Differentiation of
hES cells into motoneurons was demonstrated shortly after (Li et al., 2005, Shin et al.,
2005). The electrophysiological properties of mES cell-derived motoneurons mimic
those observed in the spinal cord including the ability to fire multiple action potentials
(Miles et al., 2004). Shh can be replaced with small molecule agonists of the Shh
signaling pathway, including purmorphamine and smoothened agonist (SAG), leading to
more efficient conversion of ES cells and hiPSCs into motoneurons (Li et al., 2008,
Wichterle and Peljto, 2008, Hu and Zhang, 2009).
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The positional identify of RA and Shh-induced motoneurons was analyzed by
Peljto and colleagues and determined to be cervical spinal level motoneurons expressing
predominantly Hox5a (Peljto et al., 2010). This reflects the normal developmental
dependence of the hindbrain and cervical spinal cord on RA signaling. More caudal
thoracic and lumbar motoneurons were generated using a RA free induction that relied
on endogenous Wnt and FGF signaling for caudal specification. The absence of RA
also shifted cells from a predominant medial motor column identity to a more lateral
medial column identity. In a recent study, combining small molecule agonists
purmorphamine and SAG during induction of hES cells and hiPSCs promoted a limb
innervating motoneuron phenotype compared to induction with the recombinant Shh
protein alone (Amoroso et al., 2013). In this case ES cells and hiPSCs were first neurally
induced by dual SMAD inhibition. All conditions led to a cervical specification of
motoneurons. Many different sub-types of motoneurons can be differentiation from
mES cells, hES cells, and hIPSCs for position specific applications.

1.5 Combination Therapies for Spinal Cord Injury
Several strategies have been developed to address the individual aspects of CNS
trauma including limiting inflammation and secondary injury, remodeling injured tissue,
neutralizing inhibitory molecules, increasing trophic support and replacing neural cell
populations. Functional recovery in studies targeting a single component, however, is
often modest. Combining therapies may help overcome multiple barriers to
regeneration and provide synergistic effects on functional recovery. Here we review the
most common and recent combination therapies that include the use of two or more
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individual strategies to promote regeneration. While the majority of the work has been
performed in SCI, successful therapies can be extrapolated to other types of CNS
trauma.

1.5.1 Cell Transplantation and Biomaterial Combinations
Cell transplantation and biomaterial scaffolds each have unique advantages as
therapeutic strategies for SCI. Cells can provide a large repertoire of signaling
molecules, including anti-inflammatory cytokines and neurotrophic factors. However,
cells often fail to provide topographical guidance of regenerating axons resulting in
random growth (Blesch et al., 2002). Biomaterial scaffolds can guide regenerating axons
but cannot replace cell populations lost due to injury. Combining cellular and material
strategies may provide synergistic effects and enhance recovery following SCI.
Additionally, scaffolding can serve as a vehicle for cell transplantation, enhancing
survival and engraftment at the injury site.
Many groups have demonstrated improved regeneration following
transplantation of Schwann cells directly into the spinal cord, however recovery is often
modest (Takami et al., 2002). Schwann cells play important roles in peripheral nerve and
spinal cord injuries including debris clearance and trophic support of regenerating axons
(Xu et al., 1995, Oudega and Xu, 2006). The addition of Schwann cells to biomaterial
scaffolds as a combination therapy may enhance recovery following SCI. In several
studies, Schwann cells were reported to promote neural regeneration through poly
(lactic co-glycolic) acid (PLGA) scaffolds implanted into a complete transection model
(Moore et al., 2006, Olson et al., 2009, Chen et al., 2011a), however; functional recovery
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was not improved (Olson et al., 2009). One potential benefit of combining cellular
transplantation and scaffolds is the improved survival of transplanted cells. The effect
of scaffold composition on Schwann cell survival in the spinal cord lesion was tested
following contusive spinal cord injury (Patel et al., 2010). Greater cell survival,
neurofilament density within the lesion, and functional recovery were observed when
Schwann cells were transplanted in Matrigel compared to no scaffold or methylcellulose
(MC). Matrigel, however, is generated from a sarcoma cancer cell line and is not
approved for clinical use (Kleinman et al., 1982, Kleinman et al., 1986).
Transducing Schwann cells to express neurotrophins prior to seeding within
scaffolds can also be used in combination strategies. Schwann cells modified to express
glial derived neurotrophic factor (GDNF) have been shown to decrease glial scarring
and increase neural regeneration (Deng et al., 2011). When mixed with Matrigel and
seeded into guidance channels of PAN/PVC scaffolds, GDNF-expressing Schwann
cells induced migration of host astrocytes into the scaffold and reduced the presence of
CSPGs at the scaffold interface. In another study, Schwann cells expressing NT-3
improved neuronal survival and locomotor recovery when injected into collagen
scaffolds with NSCs. Independent verification is necessary to determine the clinical
applicability of combination therapies involving neurotrophins, Schwann cells, and
biomaterial scaffolds. Furthermore, the use of Schwann cells is limited by the lack of
suitable sources. In most studies, Schwann cells are isolated from peripheral nerves
requiring loss of function at the donor site (Kreider et al., 1981). Several weeks are
needed to expand Schwann cells to obtain a sufficient number of cells for
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transplantation, thus limiting their use in acute treatments. Additional work is therefore
needed to generate alternative sources of Schwann cells.
Transplantation of BMSCs has been shown to reduce cavitation of the injury
site, enhance regeneration, and promote functional recovery (Hofstetter et al., 2002,
Tohda and Kuboyama, 2011). Recent studies have tested the efficacy of BMSCs in
combination strategies utilizing scaffolds. When seeded in chitosan conduits, BMSCs
led to improved spinal cord motor evoked potential amplitude (Chen et al., 2011b).
However, no significant improvements were observed in locomotor recovery.
Furthermore, BMSCs reduced the lesion size and the presence of macrophages. In
another study, BMSCs expressing BDNF improved GAP-43+ fiber regeneration in
Matrigel scaffolds and greater functional recovery versus Matrigel scaffold controls, but
were not statistically different from unmodified BMSCs in Matrigel (Koda et al., 2007).
Human BMSCs transplanted in collagen scaffolds reduced the lesion size and improved
spatial learning and functional recovery following traumatic brain injury (TBI) (Lu et al.,
2007). While BMSCs show promise for repair following SCI and TBI, inconsistencies in
reported locomotor recovery currently limits their use.
CNS-derived NSCs and ESNPCs have been shown to replace neural
populations following SCI. NSCs and ESNPCs can improve remyelination and
integrate into axonal pathways, promoting functional recovery (Vroemen et al., 2003,
Keirstead et al., 2005, Karimi-Abdolrezaee et al., 2006, Hooshmand et al., 2009). Early
work involving murine NSCs in PLGA scaffolds demonstrated that the combination
could enhance functional recovery (Teng et al., 2002). Brain-derived NSCs seeded in
guidance channels in chitosan scaffolds increased the tissue bridge area following
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complete transection (Nomura et al., 2008). Recently, human NSCs in PLGA scaffolds
were transplanted into a non-human primate model of SCI (Pritchard et al., 2010).
However, sufficient animals for statistical analysis were not used, so the outcomes were
inconclusive. Following cortical impact TBI, laminin-based scaffolds containing NSCs
improved spatial learning. Improvements in cognitive function where not observed in
scaffold only or NSC only treatment groups (Tate et al., 2009). The transition of NSCs
into the clinical setting, however, is hindered by limited differentiation of NSCs into
neurons in vivo and lack of appropriate donor tissue for human NSCs (Cattaneo and
McKay, 1990).
ESNPCs may provide an alternative to NSCs. When transplanted in fibrin
scaffolds containing NT-3 and platelet-derived growth factor (PDGF), ESNPCs
enhanced functional recovery in a sub-acute hemisection model (Johnson et al., 2010a).
Prolonged release of growth factors, however, increased tumor formation from
transplanted ESNPCs. Methods for purification of cell populations prior to transplant
are necessary before the full utility of ESNPCs can be realized. Induced pluripotent
stem cell-derived NSCs may provide an alternative to ESNPCs, however, more work is
needed to increase purity and determine the utility of this cell type.

1.5.2 Cell Transplantation and Growth Factor Delivery Combinations
In the developing CNS, neurotrophic factors promote the directed growth and
survival of many types of neurons. The introduction of neurotrophins to the injured
spinal cord can promote neuronal survival and enhance regeneration of specific
ascending and descending axonal pathways. Notably, BDNF promotes growth of
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rubrospinal, raphespinal, cerulospinal and reticulospinal pathways while NT-3 elicits
sprouting and growth of corticospinal and dorsal column sensory axons (for a complete
review see (Lu and Tuszynski, 2008)) (Grill et al., 1997, Ye and Houle, 1997, Menei et
al., 1998, Bradbury et al., 1999). NGF and GDNF also support growth of regenerating
axons, however, their potential for promoting aberrant growth of pain-associated
nociceptive spinal axons may reduce their desirability for SCI (Tuszynski et al., 1994,
Blesch and Tuszynski, 2003, Ramer et al., 2003). Combining neurotrophic factor
delivery with cell transplantation or biomaterial scaffolds may provide synergistic effects
to improve functional recovery.
Coupling cell transplantation with neurotrophic factor delivery may enhance
repair following SCI. OPCs modified to express ciliary neurotrophic factor survived to
a greater extent compared to unmodified OPCs following transplantation into the
contused spinal cord (Cao et al., 2002). Survival correlated with enhanced remyelination
of spared axons and recovery of locomotor function. Co-transplantation of NT-3
expressing Schwann cells with NSCs improved locomotor recovery over transplants of
unmodified Schwann cells and NSCs (Guo et al., 2007). Axonal growth is commonly
reported in response to cellular delivery of neurotrophins (Grill et al., 1997, Menei et al.,
1998, Golden et al., 2007, Koda et al., 2007); however, functional recovery is variable
and often modest. Many cells endogenously express neurotrophins, thereby reducing
the effect of additional secretion on locomotor recovery. Coupling enhanced
neurotrophin release with other cell-type specific functions, such as remyelination by
OPCs, can improve the utility of these combination therapies.
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1.6 Concluding Remarks
In this introduction, the promise of cell replacement therapies, especially ES
cell-based therapies, was demonstrated through review of published literature. The
potential and associated caveats of combination therapies involving biomaterial
scaffolds, growth factor delivery, and cell transplantation was also discussed. The
following studies were developed to overcome the most apparent pitfalls of ES cellbased cell replacement therapies: tumorgenicity and heterogeneity of transplanted cell
populations.
In the first study, high purity pMNs were obtained and characterized. A new
mouse ES cell line (P-Olig2) was developed in collaboration with the laboratory of Dr.
David Gottlieb. In this cell line, expression of the puromycin resistance enzyme was
driven by gene regulatory elements of the Olig2 in the P-Olig2 cell line. Puromycin
exposure was used to isolate pMN cells from the heterogeneous cell culture. The
resulting cell populations were characterized for pMN enrichment. This study evaluated
the feasibility of antibiotic selection for purification of ES cell-derived populations.
In the second study, high purity pMNs were assessed for their ability to survive
and differentiate in fibrin scaffolds. The effect of two different growth factor
combinations (NT-3 and GDNF or NT-3 and PDGF) on cell differentiation with or
without the HBDS was studied as growth factors have been shown to modulate
differentiation of ESPNCs. The ability of in vitro cultures to predict in vivo
differentiation was examined following a 2 week transplantation study in a sub-acute
dorsal hemisection model of SCI. The sub-acute model was chosen as it has been
previously shown to permit greater cell survival. This study examined the ability of
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purified pMN populations to differentiate and survive within combination therapies for
SCI.
Finally, the third study focus on the development of high-purity ES cell-derived
motoneurons. High purity motoneuron populations are difficult to obtain, especially
from ES cells. Many methods have been developed for isolating motoneurons from
fetal spinal tissue but are not suited well for ES cell-derived motoneurons. Small
enhancer elements for the motoneuron transcription factor Hb9 were used to drive
puromycin resistance in motoneurons with subsequent purification by puromycin
exposure. The ability to generated pure mature neuronal ES cell-derived cultures was
investigated.
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Chapter 2*
Transgenic Enrichment of Mouse Embryonic Stem
Cell-derived Progenitor Motor Neurons
2.1 Abstract
Embryonic stem (ES) cells hold great potential for replacing neurons following
injury or disease. The therapeutic and diagnostic potential of ES cells may be hindered
by heterogeneity in ES cell-derived populations. Drug selection has been used to purify
ES cell-derived cardiomyocytes and endothelial cells but has not been applied to specific
neural lineages. In this study we investigated positive selection of progenitor motor
neurons (pMNs) through transgenic expression of the puromycin resistance enzyme,
puromycin N-acetyl-transferase (PAC), under the Olig2 promoter. The protein-coding
region in one allele of Olig2 was replaced with PAC to generate the P-Olig2 cell line.
This cell line provided specific puromycin resistance in cells that express Olig2, while
Olig2− cells were killed by puromycin. Positive selection significantly enriched
populations of Olig2+ pMNs. Committed motoneurons (MNs) expressing Hb9, a
common progeny of pMNs, were also enriched by the end of the selection period.
Selected cells remained viable and differentiated into mature cholinergic MNs and
oligodendrocyte precursor cells. Drug resistance may provide a scalable and inexpensive
method for enriching desired neural cell types for use in research applications.

*Portions of this work were published in McCreedy, DA et al. Stem Cell Res. 2012 May; 8(3):368-78 and
were reprinted with permission of the publisher.
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2.2 Introduction
In most neurological disorders, neurogenesis is insufficient to replenish lost
neuronal populations. Endogenous stem cell populations are hindered by limited
numbers, variable proliferation in response to disease, and in some cases, differentiation
into glia rather than neurons (Baker et al., 2004, Yang et al., 2006, Meletis et al., 2008,
Barnabe-Heider et al., 2010). ES cells can be differentiated into specific neuronal
subtypes and may be useful for cell replacement strategies in the central nervous system
(Sonntag et al., 2007). Transplantation of ES cell-derived dopaminergic neurons and
cholinergic MNs has been shown to promote partial recovery from Parkinson’s-like
symptoms and spinal cord injury, in rodent models (Roy et al., 2006, Erceg et al., 2010).
Heterogeneous populations arising from differentiation of ES cells, however, currently
limit the efficacy of such treatments (Gogel et al., 2011). Strategies for controlled
differentiation of ES cells and the subsequent enrichment ES cell-derived cells types are
therefore critical to the translation of ES cell-based therapies into a clinical setting.
Directed differentiation of ES cells into spinal MNs can be achieved following
exposure to retinoic acid (RA) and sonic hedgehog (Shh) (Wichterle et al., 2002,
Wichterle and Peljto, 2008). During this process, ES cells first differentiate into pMNs
expressing the basic helix-loop-helix transcription factor Olig2 (Mizuguchi et al., 2001,
Novitch et al., 2001). These cells can commit to the MN fate by downregulating Olig2
and expressing the homeodomain (HD) transcription factors Islet 1 (Isl1) and Hb9, also
known as Mnx1 (Pfaff et al., 1996, Arber et al., 1999, Mizuguchi et al., 2001, Novitch et
al., 2001). Despite optimization, differentiation protocols for pMNs result in a
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heterogeneous population of cells including other ventral spinal progenitor cells
(Wichterle et al., 2002). Hb9+-committed MNs compose only 15-50% of the total
culture after differentiation of ES cells (Deshpande et al., 2006, Wichterle and Peljto,
2008). Low-purity cultures give rise to multiple types of spinal interneurons, therefore
subsequent enrichment may be necessary (Deshpande et al., 2006).
Greater pMN purity can be obtained by fluorescence-activated cell sorting
(FACS) of a transgenic ES cell line that expresses GFP under the Olig2 gene regulatory
elements (GRE) (Xian et al., 2003, Xian and Gottlieb, 2004, Xian et al., 2005). This
method, however, requires expensive equipment and must be performed at a centralized
facility, risking contamination. Gradient centrifugation can enrich spinal MNs from the
mouse embryonic lumbar spinal cord and human ES cells, but has not been optimized
for mouse ES cell-derived MNs (Wada et al., 2009, Wiese et al., 2010). Transgenic
selection may provide a low-cost alternative and can be performed directly in the culture
dish. Puromycin resistance through expression of the enzyme PAC has been shown to
allow enrichment of ES cell-derived cardiomyocytes and endothelial cells in transgenic
lines (Marchetti et al., 2002, Kolossov et al., 2006, Anderson et al., 2007, Kim and von
Recum, 2009), but has not been used to enrich specific neural populations.
In this study, we investigated whether transgenic selection could help to enrich
low-purity populations that commonly result from pMN differentiation protocols. We
generated a new heterozygous “knock in” mouse ES cell line (P-Olig2) where the
protein-coding region in one allele of Olig2 was replaced with PAC, allowing for
positive selection of Olig2+ pMNs during the differentiation. Olig2 expression was
analyzed during directed differentiation of ES cells into pMNs using the Shh signaling
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agonist, purmorphamine (Wu et al., 2004, Sinha and Chen, 2006). Puromycin-treated
cells were assessed for expression of pMN-specific markers and differentiation into
pMN progeny, including MNs and oligodendrocytes. This study demonstrates the first
use of puromycin resistance for positive selection of a specific population of neural
progenitor cells.

2.3 Materials and Methods
2.3.1 Embryonic Stem Cell Culture
The RW4 ES cell line was used to generate and characterize the P-Olig2 cell
line. Olig2 expression was characterized using the G-Olig2 ES cell line that expresses
GFP under the control of the Olig2 GRE (Xian et al., 2003, Xian and Gottlieb, 2004,
Xian et al., 2005). ES cells were grown in complete media consisting of Dulbecco’s
modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10%
newborn calf serum (Invitrogen), 10% fetal bovine serum (Invitrogen), 10 µM
thymidine (Sigma, St. Louis, MO), and 30 µM of each of the following nucleosides:
adenosine, cytosine, guanosine, and uridine (Sigma). Cells were passaged at a 1:5 ratio
every 2 days and seeded on a new T25 flask coated with a 0.1% gelatin solution (Sigma).
After seeding, 1000 U/ml leukemia inhibitory factor (LIF; Millipore, Billerica, MA) and
100 µM β-mercaptoethanol (BME; Invitrogen) were added to the media to maintain the
undifferentiated state of the ES cells without the need for a feeder cell layer.
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2.3.2 Generation of P-Olig2 ES Cells
The P-Olig2 cell line was generated from the RW4 line. Approximately 1x107
RW4 ES cells were resuspended in electroporation buffer with 10-15 µg of ScaIlinearized P-Olig2 targeting vector. The targeting vector was constructed from a
Gateway-compatible plasmid (pStartK) incorporating the Olig2 locus with the Olig2
open reading frame replaced by a dual resistance cassette consisting of from 5’ to 3’:
Asc1 site, Kozak sequence, puromycin cassette with bgh polyA signal (PKO-Select
Puro, Agilent Genomics, Santa Clara, CA), floxed phosphoglycerate kinase I promoter
driving the neomycin phosphotransferase gene (PGK-neo) with bgh polyA signal, and
AscI site (Kozak, 1986, Thomas and Capecchi, 1987, Wu et al., 2008). Cells were
electroporated using an Amaxa nucleofector II (Lonza, Basel, Switzerland) at 0.23kV
and 960µF in a 0.4 cm cuvette (Bio-Rad, Hercules, CA). Following electroporation, cells
were seeded on gelatin coated 10cm dishes for 24 hours then dosed with G418 (200
µg/ml, Invitrogen) and 1-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (FIAU;
100 nM, Movarek Biochemicals, Brea, CA) for positive and negative selection
respectively. After 8 days, resistant clones were picked and seeded on a mouse
embryonic fibroblast STO monolayer in individual wells of a 96 well plate to promote
growth of low density ES cell clones. Clones were screened for targeting events by PCR
using standard methods. Targeted clones were detected and further characterized.

2.3.3 Southern Hybridization
Genomic DNA was isolated from RW4 and P-Olig2 ES cells using the
ArchivePure DNA Cell/Tissue and Tissue Kit (5 Prime, Gaithersburg, MD). DNA34

binding proteins were digested with Proteinase K. Genomic DNA was digested with
200 U HindIII or 50 U SpeI overnight at 37°C. Restriction enzymes were re-applied for
an additional hour then DNA was ethanol precipitated. DNA restriction fragments were
separated by electrophoresis. DNA was transferred to a Hybond-XL (GE Healthcare
Biosciences, Piscataway, NJ) membrane and crosslinked using a UV Stratalinker 2400
(Stratagene). DNA probes were prepared with the Rediprime Kit (GE Healthcare
Bioscience) and [32P] dCTP (Perkin-Elmer, Waltham, Massachusetts). Probes were
purified using illustra ProbeQuantG-50 columns (GE Healthcare Biosciences). Blots
were hybridized in Rapid hybe (GE Healthcare Biosciences) for two hours at 65°C, then
washed and visualized by autoradiography.

2.3.4 Cre-excision
To remove the floxed PGK-neo resistance cassette, 2x106 ES cells were
transfected with 5 µg of Cre recombinase expressing plasmid (p1411, gift of Tim Ley,
Washington University). Removal of the PGK-neo cassette was confirmed using
junction PCR. Cre-excised clones were further subcloned and re-validated by PCR and
neomycin sensitivity.

2.3.5 Live Dead Assay
Live/Dead reagent (Invitrogen) consisting of calcien-AM and ethidium
homodimer was used to visualize live and dead cells, respectively. Wells were washed
with Dulbecco’s PBS and incubated with 1x Live/Dead reagent for 30 min at room
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temp. Fluorescent images were captured using MetaVue image analysis software
(Molecular Devices, Sunnyvale, CA) and a Nikon TE200S fluorescence microscope.

2.3.6 pMN Differentiation
For pMN induction, ES cells were exposed to RA (Sigma) and purmorphamine
(EMD, Gibbstown, NJ) in a 2-/4+ differentiation protocol. One million ES cells were
aggregated into embryoid bodies (EBs) in 100-mm Petri dishes coated with a 0.1% agar
solution in DFK5 media consisting of DMEM:F12 base media (Invitrogen)
supplemented with 5% knockout serum replacement (Invitrogen), 50 µg/ml apotransferrin (Sigma), 50 µM non-essential amino acids (Invitrogen), 5 µg/ml insulin
(Sigma), 30 nM sodium selenite (Sigma), 100 µM β-mercaptoethanol, 5 µM thymidine,
and 15 µM of the following nucleosides: adenosine, cytosine, guanosine, and uridine.
EBs were allowed to form for 2 days in the absence of inducing factors, then split 1:5
and transferred to 6-well plates coated with 0.1% gelatin solution. Once plated, the EBs
were grown for an additional 4 days in DFK5 supplemented with 2 µM RA and 250 nM
– 1.5 µM purmorphamine. Media was changed every 2 days. In selected cultures, 2
ng/ml puromycin (Sigma) was added during the final 2 days of differentiation.

2.3.7 Quantitative Real Time Polymerase Chain Reaction
The relative expression level of progenitor cell transcription factors and markers
for MN differentiation were assessed using quantitative real-time polymerase chain
reaction (qRT-PCR). EBs were lysed with Trizol reagent (Invitrogen) and RNA was
isolated using an RNeasy kit (Qiagen, Germantown, MD). Isolated RNA was used to
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synthesize cDNA for qRT-PCR analysis using the TaqMan 2-Step RNA-to-CT Mini Kit
(Applied Biosystems, Carlsbad, CA). TaqMan Gene Expression Assays (Table 1, Applied
Biosystems), TaqMan Gene Expression Master Mix (Applied Biosystems) and cDNA
were combined and qRT-PCR was performed using an Applied Biosystems 7000
thermocycler with the following PCR protocol: 50ºC for 2 min, 95ºC for 10 min, and 40
cycles of 95ºC for 15 s, 55ºC for 30 s and 72ºC for 30 s. 6-carboxyfluorescein (FAM)
fluorescent detection occurred during each 72ºC cycle. Relative mRNA expression was
reported as the number of cycles necessary for fluorescent intensity to increase
exponentially, referred to as the threshold cycle (Ct). All target genes were normalized to
ß–actin to account for differences in total mRNA content. Expression in EBs induced
with 2 µM RA and 250 nM, 500 nM, or 1 µM purmorphamine was determined using the
comparative ∆Ct method, with EBs receiving neither RA nor purmorphamine serving as
the control group (Schmittgen and Livak, 2008). Results are reported as a fold
difference in relative RNA expression over control EBs (n=3 for each condition).

2.3.8 Flow Cytometry
Differentiated ES cell cultures were stained immediately following the 2-/4+
treatment protocol for flow cytometry analysis. Cultures were dissociated with trypsinEDTA (0.25%; Invitrogen) for 15 min and triturated to form single cell suspensions.
Excess volume of complete media was added to quench the trypsin, and cells were
centrifuged for 5 min at 230xg. The media was aspirated and cells were fixed with 1%
paraformaldehyde (Sigma). After fixation, the cells were permeabilized with 0.5%
saponin (Sigma) solution for 20 min, and then blocked in 0.1% saponin solution
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containing 5% normal goat serum (NGS; Sigma). Cell suspensions were then incubated
for 30 min in 0.1% saponin solution containing 2% NGS and one of the following
primary antibodies: Nestin (Iowa Hybridoma Bank; 1:10), Isl1 (Iowa Hybridoma Bank;
1:50), Hb9 (MRN2; Iowa Hybridoma Bank; 1:25), and Olig2 (Millipore; 1:500). Cells
were washed with PBS and appropriate Alexa Fluor secondary antibodies (1:200;
Invitrogen) diluted in 0.5% saponin with 2% NGS were applied for 30 min. Finally cells
were washed with PBS and incubated with Hoechst (1:1000; Invitrogen) for 5 min.
Stained cell suspensions were analyzed using a Canto II flow cytometer (Becton
Dickinson, Franklin Lakes, NJ). For each group, 10,000 events were recorded.
Subsequent analysis was performed using FloJo software (FloJo, Ashland, OR). Prior to
population gating, debris was removed based on forward scatter versus side scatter and
Hoechst fluorescence versus forward scatter plots. Flow cytometry control groups,
consisting of cells stained with the secondary antibody only, were used to determine
quadrant population gating parameters. Flow cytometry results are presented as the
percentage of cells staining positive for each marker out of the total live cell population.

2.3.9 Immunocytochemistry
Cell distribution and identity was assessed in differentiated cultures using
immunocytochemistry (ICC). Cell cultures were fixed with 1% paraformaldehyde for 30
min then permeabilized in 0.01% Triton X (Sigma) for 15 min. The cells were blocked
with 5% NGS for 1 hour at 4°C and incubated overnight at 4°C in 2% NGS solution
with one or more of the following primary antibodies: Oct 4 (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA), Olig2 (1:500), Isl1 (1:20), Hb9 (1:20), Nestin (1:10),
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Neurofilament (NF, DSHB, 1:25), choline acetyl transferase (ChAT, Millipore, 1:400),
oligodendrocytes (RIP, Millipore, 1:5000), and oligodendrocyte marker 4 (O4,
Milllipore, 1:500). Primary antibody staining was followed by 3 washes in an excess
volume of PBS for 15 min each. Each culture was then stained with the appropriate
Alexa Fluor secondary antibodies (Invitrogen) for 1 hour at 4°C followed by an
additional 3 washes in PBS. Cell nuclei were stained with the nuclei binding dye
Hoechst (1:1000). Fluorescent images were captured using a MICROfire camera
attached to an Olympus IX70 inverted microscope. Images were analyzed using Image
Pro Express (Media Cybernetics, Silver Spring, MD).

2.3.10 Undifferentiated ES Cells
To quantify the occurrence of Oct4+ undifferentiated stems cells following the
2-/4+ differentiation protocol, P-Olig2 cultures were fixed and stained with the Oct4
antibody. EBs containing at least one Oct4+ nuclei were counted and divided by the
total number of EBs to determine the fraction of EBs containing undifferentiated stem
cells. At least 50 EBs per sample were assessed for Oct4 expression.

2.3.11 Extended Differentiation of pMNs
For pMN differentiation, 24-well plates were pre-coated with 0.01%
poly(ornithine) solution (Sigma) then coated with 0.01 mg/mL laminin solution
(Invitrogen) overnight. Induced 2-/4+ EBs were dissociated and plated at a density of
100,000 cells/ml in DFK5 media. After 5 days, media was replaced with Neurobasal

39

media (Invitrogen) supplemented with 0.1% bovine serum albumin (Sigma) and 2% B27
(Invitrogen). Cells were allowed to differentiate an additional 9 days.

2.3.12 Statistical Analysis
For qRT-PCR and flow cytometry analyses, 3 replicates of each condition were
performed. Statistical analysis was performed in Statistica software (version 5.5; StatSoft;
OK). Multiple comparisons statistics were accomplished using Scheffe’s post hoc test
for analysis of variance (ANOVA) with a 95% confidence level. Values are reported as
the mean plus or minus standard deviation.

2.4 Results
2.4.1 Olig2 expression during differentiation of ES Cells
To determine the effect of Shh signaling levels on directed differentiation of ES
cells into pMNs, we analyzed mRNA levels in response to increasing concentrations of
purmorphamine, a Shh agonist, using quantitative real time (RT)-PCR. ES cells were
exposed to 2 µM retinoic acid (RA) and 250 nM, 500 nM, or 1 µM purmorphamine.
Relative mRNA levels were analyzed at the end of the 2-/4+ differentiation protocol and
were compared to control cells that did not receive RA or purmorphamine (n=3 for all
conditions). Increasing the purmorphamine concentration from 250 nM to 1 µM led to
downregulation of Dbx2 and Irx3, two transcription factors found in p1 and p2
progenitor (more dorsal) domains, respectively (Figure 2.1, Figure 2.2A). The mRNA
levels for Pax6, which is expressed in the p1, p2, and pMN domains, did not change
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with concentration. Nkx2.2 mRNA levels were too low for detection even at the highest
concentration of purmorphamine (data not shown). Olig2 expression significantly
increased with exposure to 1 µM purmorphamine compared to 250 nM and 500 nM
purmorphamine (Figure 2.2B). HD transcription factors Isl1 and Hb9 expressed during
commitment of pMNs to the MN fate were upregulated with 1 µM purmorphamine,
similar to Olig2. Finally, 1 µM purmorphamine led to an increase in mRNA for choline
acetyltransferase (ChAT), an enzyme found specifically in mature MNs.

Figure 2.1 Schematic of transcription factors expressed in spinal progenitor domains. Ventralto-dorsal gradient of sonic hedgehog (Shh) and relative position of spinal progenitor domains
in the ventral neural tube are shown on the left. The pattern of transcription factor expression
in each domain is shown on the right.
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Figure 2.2 Transcription factor expression during directed differentiation of ESCs. (A):
Expression of p1 and p2 progenitor genes in ESCs differentiated with the Shh signaling
agonist, purmorphamine, and retinoic acid (RA) using a 2-/4+ differentiation protocol. Data
are expressed as the fold difference in mRNA levels compared to ESCs differentiated
without purmorphamine and RA. (B): Expression of pMN and MN specific genes in
differentiated ESCs. * indicates p < 0.05 for that gene compared to ESCs exposed to 250
nM purmorphamine. # indicates p < 0.05 for that gene compared to ESCs exposed to 500
nM purmorphamine. Abbreviations: FP, floor plate; ChAT, choline acetyl transferase; Isl1,
Islet 1.

2.4.2 Heterogeneity in differentiated cultures
To characterize the heterogeneity of the cell population resulting from
differentiation of ES cells, we utilized a transgenic ES cell line expressing GFP under
the Olig2 GRE, G-Olig2 (Xian and Gottlieb, 2004). GFP fluorescence can persist for
several days after transcription, allowing for identification of pMNs and their recent
progeny during differentiation. By visual inspection of GFP fluorescence, pMNs could
be easily separated from other spinal progenitor cells that differentiate into spinal
interneurons rather than MNs.
G-Olig2 ES cells were differentiated using 1 µM purmorphamine and 2 µM RA
and analyzed by flow cytometry. At the end of the 2-/4+ differentiation protocol, 61.6 ±
4.5% of cells expressed GFP (n = 3). This percentage was approximately 3-fold higher
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than expression of Olig2 found with traditional antibody staining, suggesting that GFP
fluorescence persists in recent pMN progeny as expected. GFP- cells were consistently
found migrating away from EBs and displayed a broad flat morphology typical of
astrocytes or astrocyte precursor cells (ASPs) (Figure 2.3 D-F; white arrows). These cells
may originate from the p2 progenitor domain that gives rise to ASPs in vivo (Muroyama
et al., 2005). Additional GFP- cells were present within EBs with a similar morphology
to Olig2+ pMNs and may represent progenitor cells from adjacent progenitor domains
(white asterisk).

2.4.3 Generating the P-Olig2 Cell Line
The P-Olig2 cell line was generated using a targeting vector with a resistance
cassette in the open reading frame of the Olig2 gene surrounded by two regions
homologous to the Olig2 locus. RW4 ES cells were electroporated with the P-Olig2
targeting vector and homologous recombination occurred as illustrated in (Figure 2.4A).
To confirm targeted insertion, novel junctions were detected using short arm junction
PCR. Successful integration resulted in a 2.1 kb fragment spanning from inside the
targeting construct into neighboring genomic DNA (Figure 2.4B). The addition of the
resistance cassette increased the distance between Hind III sites within the Olig2 locus
from 4.8 kb to 6.7 kb as observed by Southern analysis (Figure 2.4C). Only the 4.8kb
band was observed in control RW4 cells while both bands were observed in the P-Olig2
cell line. The appearance of both bands confirms that only one of the two Olig2 loci
was targeted. Following insertion, the floxed PGK-neo cassette was excised with Cre
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Figure 2.3 Heterogeneity following directed differentiated of G-Olig2 ESCs. (A): Phase
contrast image of differentiated G-Olig2 ESCs following exposure to purmorphamine and
RA. (B): Expression of green fluorescent protein (GFP) in (A) showing cells that have
expressed Olig2 during differentiation. (C): Corresponding Hoechst staining showing cell
nuclei. Scale bars = 100 µM. (D-F) Close inspection of GFP- cells (white arrows) with
astrocyte-like morphology that did not differentiate into pMNs expressing Olig2. Additional
GFP- cells with progenitor-like morphology were found within EBs (white asterisk). Scale
bars = 50 µM.
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recombinase as confirmed using PCR by a new 350 bp band (Figure 2.4D). The final
cell line contained a promoter-less PAC cassette driven by the Olig2 GRE (Figure
2.5A).
To determine the specificity of PAC expression, P-Olig2 and RW4 ES cells were
differentiated into pMNs, and the expression of Olig2 and PAC mRNA was assessed
using PCR. Olig2 and PAC mRNA was not observed or present at very low levels in ES
cells and ES cells aggregated into EBs (Figure 2.5B). Following the 2-/4+ differentiation
protocol, Olig2 mRNA levels were elevated in both P-Olig2 and RW4 cell lines. PAC
mRNA, however, was specific to the P-Olig2 cell line. Specificity of PAC expression in
the P-Olig2 cell line was confirmed by sensitivity to puromycin. Few P-Olig2 ES cells
survived following exposure to puromycin for 48 hrs (Figure 2.5C) since the Olig2 gene
is off or expressed at very low levels. In contrast, many viable cells were observed in
cultures of P-Olig2 ES cells differentiated into pMNs, which express Olig2 (Figure
2.5D). Widespread cell death was still observed in the latter group, suggesting the
presence of Olig2- cells that do not express PAC and are sensitive to puromycin.

2.4.4 Enrichment of pMNs using the P-Olig2 Cell Line
To determine whether transgenic selection enriched the cell population for
pMNs and committed MNs, P-Olig2 cells were differentiated using 2 µM RA and 1.5
µM purmorphamine with a 2-/4+ differentiation protocol. Puromycin was added during
the last two days to select for Olig2+ pMNs (Figure 2.6A). Control groups consisted of
RW4 and P-Olig2 cells not receiving puromycin. Similar to G-Olig2 cell cultures, broad
Olig2- cells were observed migrating out of the EB in the control P-Olig2 group (Figure
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Figure 2.4 Knock-in to replace Olig2 ORF with PAC gene. (A): Olig2 gene is a schematic of
the Olig2 gene. The smaller black boxes represent the two exons of the Olig2 gene with the
ORF (large black box) located in the second exon. The 5’ probe and H (HindIII) sites used
for Southern blots are indicated. P-Olig2 vector shows the targeting vector with the PAC and
floxed neo cassette in place of the ORF. P-Olig2-neo is the predicted knock-in product with
the predicted 6.7Kb HindIII fragment and the 2.1 Kb junction PCR product shown. P-Olig2
shows the engineered gene after Cre-excision of the floxed neo cassette. (B): Junction PCR of
control RW4 cells and targeted cells. Amplified DNA is absent in the RW4 cells but present
in the targeted (P-Olig2) cells. (C): Southern blots- RW4 parental cells have native 4.8 Kb
HindIII band; targeted (POlig2) cells have additional 6.7 Kb band. (D) Cre-excision of neo
cassette- PCR reactions across neo cassette show amplified DNA in Cre+ cells but not in
untreated (Cre-) cells.
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2.6B). In cultures with puromycin, these cells were not present. Cellular debris localizing to the
same region suggests that puromycin-induced cell death occurred in Olig2- cells. The majority of
surviving cells had a progenitor-like morphology and expressed Olig2 or Hb9.

To assess cell differentiation in control and selected cultures, cells were stained
at the end of the differentiation protocol with phenotype-specific markers and analyzed
using flow cytometry. Puromycin selection did not affect the distribution of Nestin+
cells, suggesting that the majority of cells were neural cells. The percentage of Olig2+
cells increased significantly from 21.9 ± 5.9% to 48.7 ± 7.3% when selected with
puromycin (Figure 2.7A-B). Hb9+ populations were enriched from 20.6 ± 7.9% to 58.5
± 1.5%. Similar enrichment was observed for Isl1. No significant differences were
found for any marker between the RW4 and control P-Olig2 (non-selected) groups.

2.4.5 Undifferentiated Stem Cells
To determine the effect of puromycin exposure on Oct4+ undifferentiated stem cells,
cultures were fixed and analyzed following immunocytochemistry (ICC). The overall

percentage of cells expressing the pluripotent stem cell marker Oct4 following the 2-/4+
differentiation was low (<1%) in control and selected groups (data not shown). The
fraction of 2-/4+ EBs containing at least one Oct4+ nuclei was compared between
unselected and selected P-Olig2 pMNs on day 6. Oct4+ cells were commonly found in
small groups and were limited to unselected P-Olig2 cultures (Figure 2.8A).
Approximately 10% of EBs contained undifferentiated stem cells in the absence of
puromycin (Figure 2.8B). Oct4+ nuclei were not observed in any of the cultures
selected with puromycin.
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Figure 2.5 PAC and Olig2 expression in the P-Olig2 cell line (A): Schematic of the PAC
cassette driven by the native Olig2 GRE. (B): Olig2 and PAC mRNA expression in P-Olig2 and
RW4 cell lines. Expression was analyzed in ESCs, ESCs aggregated into embryoid bodies
(EBs), and ESCs differentiated into pMNs using a 2-/4+ treatment protocol. (C): Live/dead
assay showing live cells (green) and dead cells (red) following exposure of undifferentiated POlig2 and RW4 ESCs to puromycin for 48 hours. (D): Live/dead assay for differentiated POlig2 and RW4 EBs selected with puromycin for 48 hours. Fluorescent cell debris was
observed in the RW4 group whereas the P-Olig2 group contained whole viable cells.

48

2.4.6 Extended Differentiation of pMNs
To determine whether targeted replacement of the Olig2 gene impacted the
ability of ES cell-derived pMNs to terminally differentiate, we cultured puromycin
selected P-Olig2 cells for two weeks on laminin-coated wells. Following differentiation,
cells were assessed for expression of ChAT and neurofilament (NF) using ICC to
identify mature MNs. Cultures were also stained for oligodendrocyte marker 4 (O4) and
RIP to identify oligodendrocytes, another common progeny of pMNs. Groups of
ChAT+/NF+ neurons were abundant throughout the culture (Figure 2.9).
Oligodendrocytes expressing O4 and RIP were also present (Figure 2.9). These results
demonstrate that cells surviving the puromycin selection differentiate into neurons and
oligodendrocytes, the expected progeny of Olig2+ pMNs.

2.5 Discussion
Current protocols for differentiation of mouse ES cells are often hindered by
low efficiencies. Directed differentiation may be lead to heterogeneous ES cell-derived
populations that must be further purified to obtain the desired lineages prior to cell
culture studies or transplantation. In this study, we demonstrate that positive selection
of Olig2+ pMNs through transgenic expression of the puromycin resistance enzyme
PAC can provide a simple method for enrichment of pMNs.
Purmorphamine exhibited a dose-dependent effect on pMN gene expression
during directed differentiation of G-Olig2 ES cells. Greater concentrations of
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Figure 2.6 Positive selection of P-Olig2 ESCs differentiated using a 2-/4+ differentiation
protocol. (A): Schematic showing 2-/4+ differentiation protocol of ESCs. Puromycin was
added from day 4 and remained till day 6. (B): Immunocytochemistry analysis of P-Olig2
ESCs following differentiation and puromycin selection. Olig2+ and Hb9+ cells compose a
small fraction of the entire population in the absence of puromycin. Following puromycin
treatment, the majority of cells expressed either Olig2 or Hb9. (C): Nestin expression in
control and selected P-Olig2 cultures. The majority of cells express nestin.
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Figure 2.7 Flow cytometry results following selection. (A) Flow cytometry histograms and
gating. Solid black histograms represent secondary antibody controls. (B): Flow cytometry
analysis of RW4, non-selected P-Olig2, and puromycin selected P-Olig2 ESCs following
differentiation. * indicates p < 0.05 for that marker compared to unselected P-Olig2 group.
Scale bars = 100 µM.

Figure 2.8 Oct4 expression in P-Olig2 cells following the 2-/4+ differentiation protocol. (A):
A small group of Oct4+ nuclei in an unselected, control P-Olig2 EB. (B): Fraction of EBs
containing Oct4+ nuclei in control and selected P-Olig2 cultures. * indicates p < 0.05
compared to unselected P-Olig2 group
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purmorphamine led to a significant increase in Olig2 expression. Conversely, expression
of Dbx2 and Irx3 (more dorsal transcription factors) were reduced with increasing
concentrations of purmorphamine. Nkx2.2, which is expressed in the more ventral p3
progenitor domain, was not detected in any of the conditions tested. Based on the gene
expression data, directed differentiation appears to favor pMNs at the highest
concentration of purmorphamine tested. However, this condition still resulted in a
mixed cell population with nearly 40% of cells not expressing Olig2. This undesired
population may include cells from neighboring progenitor domains that have been
previously observed following directed differentiation of ES cells into pMNs (Wichterle
et al., 2002). Differentiation of ES cells into cells from multiple spinal progenitor
domains is potentially due to overlapping dependency on Shh signaling in the ventral
neural tube or our inability to precisely control localized concentration of
purmorphamine over the duration of the experiment. Furthermore, variations in the
responsiveness of each cell to Shh signaling may attribute to heterogeneity.
Positive selection of cardiomyocytes and endothelial cells through puromycin
resistance has been previously shown using randomly inserted resistance cassettes
containing a cell-type specific promoter (Marchetti et al., 2002, Kolossov et al., 2006,
Kim and von Recum, 2009). By knocking in PAC expression, we preserve regulatory
mechanisms for the native Olig2 gene. Expression of PAC in the final P-Olig2 cell line
recapitulated expression of Olig2 in the native allele. Specificity of the PAC cassette
driven by the native Olig2 GRE was shown by puromycin sensitivity. Cell death was
induced in puromycin treated P-Olig2 ES cells within 48 hours which is similar to the
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Figure 2.9 Immunocytochemistry performed on selected pMNs differentiated for two weeks
on laminin. (A): ChAT and respective (B): NF expression in differentiated cultures showing
mature cholinergic motoneurons. Differentiation also led to expression of (C): O4 and (D):
RIP showing immature and mature oligodendrocytes respectively. Scale bars = 100 µM.
Abbreviations: ChAT, choline acetyl transferase; NF, neurofilament; O4, oligodendrocyte
marker 4.

time-course previously described for puromycin-induced cell death (Watanabe et al.,
1995). Only when P-Olig2 ES cells were differentiated into pMNs using the 2-/4+
differentiation protocol did cells remain viable following puromycin treatment. Cell
death was still observed in differentiated ES cell cultures suggesting that only cells
having expressed Olig2 show resistance. Consistent with this hypothesis, puromycin
treatment removed all broad flat cells previously identified as Olig2-. In addition,
puromycin killed all Olig2-/Oct4+ undifferentiated stem cells. The majority of remaining
viable cells were positive for the transcription factors Olig2 or Hb9. These results
demonstrate selective resistance in pMNs and their progeny.
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Differentiation of non-selected P-Olig2 ES cells was similar to RW4 ES cells for
all markers tested in this study. Substituting PAC for one copy of the Olig2 gene did not
appear to alter differentiation of P-Olig2 ES cells into pMNs or commitment of pMNs
to the MN fate. Following puromycin treatment, Olig2+ pMNs were significantly
enriched. High purity pMNs cultures were not obtained in this study; perhaps this is due
to the persistence of the PAC enzyme in committed Hb9+ MNs. Committed MNs were
enriched nearly 3-fold and constituted the majority of cells at the end of the selection.
This population may become further enriched as additional Olig2+ pMNs commit to the
MN fate. The distribution of Nestin+ cells was not affected by puromycin treatment,
suggesting that the majority Olig2- cells killed by puromycin were neural lineage cells.
These cells could be other spinal progenitor cells that express nestin.
The long-term effects of PAC knock-in and puromycin exposure were assessed
through differentiation of puromycin-treated pMNs on laminin. Following a two week
differentiation period, ChAT+/NF+ MNs and O4+/RIP+ immature oligodendrocytes
were observed. These results demonstrate long-term viability of enriched pMNs and
committed MNs, suggesting no persistent effects of puromycin exposure.
Oligodendrocyte development from pMNs is dependent on continuous Olig2
expression (Xian and Gottlieb, 2004), and does not appear to be disturbed by the PAC
knock-in. Both MNs and oligodendrocytes have been transplanted for treatment of SCI
(Keirstead et al., 2005, Sharp et al., 2010) and are potential target populations for cell
replacement strategies in other neurological disorders including amyotrophic lateral
sclerosis and multiple sclerosis. Additional enrichment strategies can be employed to
purify individual populations of MNs or oligodendrocytes.
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Many studies in developmental biology, drug screening, and regenerative
medicine can benefit from high purity ES cell-derived cell populations. This study
demonstrates the use of puromycin resistance to select for a well-defined set of neural
progenitor cells following directed differentiation of ES cells. The methods utilized in
this study can be applied to other neural cell types to generate high-purity populations
that can accelerate the use of ES cell-based research in scientific and clinical settings.
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Chapter 3
Purified Progenitor Motor Neuron Cell Transplants
Survive and Differentiate in a Sub-acute Model of
Spinal Cord Injury
3.1 Abstract
Embryonic stem (ES) cells hold great potential for producing cell types that can
be used in cell replacement therapies following spinal cord injury (SCI).
Undifferentiated ES cells, however, persist following differentiation and can lead to
tumor formation when transplanted into the injured cord. Creating a more favorable
transplantation environment through the use of tissue-engineered biomaterial scaffolds
may enhance tumor formation by increasing proliferation of undesired cell types.
Methods for purification of ES cell-derived neural populations are necessary to
recognize the full utility of combination therapies involving biomaterials and ES cellderived transplants. We have previously developed a method for enriching ES cellderived progenitor motoneurons (pMNs) differentiated from mouse ES cells via
antibiotic selection. The enriched cell populations are devoid of pluripotent stem cells.
In this study we demonstrate the survival and differentiation of enriched pMNs within
fibrin scaffold in vitro and when transplanted into a sub-acute dorsal hemisection model
of SCI.
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3.2 Introduction
SCI is a traumatic event that leads to life-long debilitation. Loss of function
following injury is associated with severed ascending and descending tracts, cell death,
and demyelination of spared axons. Stem cell therapies can improve remyelination and
may enhance remodeling of local circuitry following SCI by replacing lost neuronal and
oligodendrocyte populations (Cummings et al., 2005, Keirstead et al., 2005, Sharp et al.,
2010, Nori et al., 2011). Pre-differentiation of ES cells can be used to obtain various
neural cell populations for treatment of SCI (Cummings et al., 2005, Keirstead et al.,
2005, Kumagai et al., 2009, Erceg et al., 2010, Rossi et al., 2010, Sharp et al., 2010).
Transplantation of stem cells into the injured cord, however, often leads to poor
survival and gliogenic differentiation (Liu et al., 2000, Cao et al., 2001, Cao et al., 2002,
Erceg et al., 2010).
Biomaterial scaffolds can improve cell survival, migration, and integration for
SCI repair (Teng et al., 2002, Nomura et al., 2008, Patel et al., 2010). Controlled
differentiation of ES cell-derived neural progenitor cells (ESNPCs) in vitro into neurons
and oligodendrocytes has been shown following encapsulation in tissue-engineered
fibrin scaffolds containing a heparin-based growth factor delivery system (HBDS) and
specific combinations of growth factors (Willerth et al., 2008). When transplanted into
the injured cord, ESNPCs encapsulated in fibrin scaffolds containing the HBDS,
neurotrophin-3 (NT3) and platelet-derived growth factor (PDGF) had improved
survival two weeks following transplantation compared to ESNPCs transplanted alone
or in unmodified fibrin (Johnson et al., 2010b). Even greater neuronal survival and
differentiation was observed when growth factors were delivered using the HBDS.
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The presence of growth factors, however, promoted rapid proliferation and
tumor formation at eight weeks following transplantation (Johnson et al., 2010a).
Growth factor delivery from the HBDS further enhanced tumor formation from a small
population of undifferentiated stem cells, possibly by creating a more permissive
transplantation environment. A small population of undifferentiated pluripotent ES
cells that persists following differentiation of ES cells into ESNPCs was hypothesized as
the main tumor producing cell type. The tumorgenicity of persistent undifferentiated
stem cells may explain terotoma formation observed in several other studies (Bjorklund
et al., 2002, Erdo et al., 2003, Amariglio et al., 2009). Methods to purify ES cell-derived
populations prior to transplantation may be necessary to reach the full potential of ES
cell-derived neural cells in combination with tissue-engineered biomaterial scaffolds.
Recently, we have demonstrated a simple and effective method for purifying ES
cell-derived pMNs (McCreedy et al., 2012). Antibiotic resistance driven by the gene
regulator elements of the pMN-associated transcription factor, Olig2, allowed for
enriched cultures for pMNs and recent progeny of pMNs following directed
differentiation of ES cells and concurrent antibiotic selection. The survival and
differentiation of high purity pMNs within the injured cord, however, has yet to be
assessed. To determine the potential for enriched ES-cell derived pMNs to serve as a
potential therapeutic for SCI, we encapsulated cells within fibrin scaffolds containing a
combination of NT3 and PDGF, or NT-3 and glial-derived neurotropic factor (GDNF)
delivered via the HBDS for two weeks in a sub-acute dorsal hemisection model of SCI.
Enriched pMNs survive within fibrin scaffolds and differentiate into motoneurons,
oligodendrocytes, and astrocytes with no growth factor associated over proliferation.
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3.3 Materials and Methods
3.3.1 Embryonic Stem Cell Culture
P-Olig ES cells were grown in complete media consisting of Dulbecco’s
modified Eagle’s Medium (Invitrogen, Carlsbad, CA) supplemented with 10% newborn
calf serum (Invitrogen), 10% fetal bovine serum (Invitrogen), 10 µM thymidine (Sigma,
St. Louis, MO), and 30 µM of each of the following nucleosides: adenosine, cytosine,
guanosine, and uridine (Sigma). Cells were passaged at a 1:5 ratio every 2 days and
seeded on a new T25 flask coated with a 0.1% gelatin solution (Sigma). After seeding,
1000 U/ml leukemia inhibitory factor (LIF; Millipore, Billerica, MA) and 100 µM βmercaptoethanol (BME; Invitrogen) were added to the media to maintain the
undifferentiated state of the ESCs without the need for a feeder cell layer.

3.3.2 pMN Differentiation
For pMN induction, ES cells were exposed to retinoic acid (RA) (Sigma) and
purmorphamine (EMD, Gibbstown, NJ) in a 2-/4+ differentiation protocol (McCreedy
et al., 2012). One million ESCs were aggregated into embryoid bodies (EBs) in 100-mm
Petri dishes coated with a 0.1% agar solution in DFK5 media consisting of DMEM:F12
base media (Invitrogen) supplemented with 5% knockout serum replacement
(Invitrogen), 50 µg/ml apo-transferrin (Sigma), 50 µM non-essential amino acids
(Invitrogen), 5 µg/ml insulin (Sigma), 30 nM sodium selenite (Sigma), 100 µM βmercaptoethanol, 5 µM thymidine, and 15 µM of the following nucleosides: adenosine,
cytosine, guanosine, and uridine. EBs were allowed to form for 2 days in the absence of
inducing factors (2-). EBs were then cultured in DFK5 supplemented with 2 µM RA
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and 1.5 µM purmorphamine for the final four days (4+). Media was changed every 2
days. In selected cultures, 4 ng/ml puromycin (Sigma) was added during the final 2 days
of differentiation.

3.3.3 In Vitro Differentiation
To prepare fibrin scaffolds, fibrinogen (50 mg/mL; EMD) was dissolved in trisbuffered saline (TBS) and dialyzed in 4L TBS overnight. Fibrinogen was sterile filtered
and the concentration measured by UV spectroscopy. The final fibrinogen
concentration was adjusted to 20 mg/mL with sterile TBS. Fibrin scaffolds (150 μl)
were formed by combining 10 mg/ml fibrinogen, 2.5 mM CaCl2 (Sigma), and 2 NIH
units/ml thrombin (Sigma) in individual wells of a 48 well plate. In delivery system
(DS) control groups, 62.5 μM heparin (Sigma) and 0.25 mM AT-III peptide were added
to each scaffold. In growth factor control groups, scaffolds contained 62.5 μM heparin,
62.5 ng NT3 (Peprotech), and 62.5 ng GDNF (Peprotech) (Hep + NT3 + GDNF) or
10 ng PDGF (Peprotech) (Hep + NT3 +PDGF). For growth factor delivery groups,
62.5 μM heparin, 0.25 mM mM AT-III peptide, 62.5 ng NT3, and 62.5 ng GDNF (DS
+ NT3 + GDNF) or 10 ng PDGF (DS + NT3 +PDGF) were added to each scaffold.
A total of 24 scaffolds were fabricated for each group. All scaffolds were washed 5
times over a 24 hour period with 500 μl TBS per wash to remove unbound delivery
system components. An individual EB containing pMNs was placed on each fibrin
scaffold and covered with a 100 μl fibrin scaffold containing 10 mg/ml fibrinogen, 2.5
mM CaCl2 (Sigma), and 2 NIH units/ml thrombin (Sigma) such that the EB remained
at the interface of the two fibrin layers. Fibrin scaffolds containing the single EB were
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incubated at 37˚C for 1 hour. 500 ul of modified DFKNB media consisting of a 1:1
ratio of DFK5 media and neuralbasal (NB) media supplemented with 2% B27 and 5
μg/ml aprotinin was added to each well. Cells were cultured for a total of 14 days with
a single media change at day 3 to NB media supplemented with 2% B27.

3.3.4 Flow Cytometry
Following the two week culture, fibrin gels were degraded with 0.25% trypsinEDTA for 15 minutes to release cells. Cells from all 24 wells for each group were
pooled in 35 mm dishes and triturated prior to quenching with an excess volume of
complete media. Cells were centrifuged for 5 min at 230xg, the media was aspirated, and
cells were fixed with 1% paraformaldehyde (Sigma). After fixation, the cells were
permeabilized with 1% saponin (Sigma) solution for 20 min, and then blocked in 0.5%
saponin solution containing 5% normal goat serum (NGS; Sigma). Cell suspensions
were then incubated for 30 min in 0.5% saponin solution containing 2% NGS and one
of the following primary antibodies: O4 (Millipore, 1:500), ChAT (Millipore, 1:500),
NeuN (Millipore, 1:100), and GFAP (ImmunoStar; 1:100). Cells were washed with PBS
and appropriate Alexa Fluor secondary antibodies (1:200; Invitrogen) diluted in 0.5%
saponin with 2% NGS were applied for 30 min. Finally cells were washed with PBS and
incubated with Hoechst (1:1000; Invitrogen) for 5 min.
Stained cell suspensions were analyzed using a Canto II flow cytometer (Becton
Dickinson, Franklin Lakes, NJ). For each group, 10,000 events were recorded.
Subsequent analysis was performed using FloJo software (FloJo, Ashland, OR). Prior to
population gating, debris was removed based on forward scatter versus side scatter and
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Hoechst fluorescence versus forward scatter plots. Flow cytometry control groups,
consisting of cells stained with the secondary antibody only, were used to determine
quadrant population gating parameters. Flow cytometry results are presented as the
percentage of cells staining positive for each marker out of the total live cell population.

3.3.5 Spinal Cord Injury and Scaffold Implantation
All experimental procedures on animals complied with the Guide for the Care
and Use of Laboratory Animals and were performed under the supervision of the
Division of Comparative Medicine at Washington University. Long-Evans female rats
(250-275 g) were anesthetized using 5% isoflurane gas and 5 mg/kg xylazine. A single
incision was created through the skin to expose the back muscle. Parallel incisions were
created through the back muscle on each side of the vertebral processes from T5-T11.
A dorsal laminectomy was performed at T8 using fine tip rongeurs to expose the spinal
cord. Spinal clamps were placed in the vertebral foramina at T7 and T9 to stabilize the
spinal cord. The dura mater was removed from the exposed cord at T8. Vitrectomy
scissors mounted to a micromanipulator were lowered 1.2 mm into the spinal cord. A
lateral incision was created across the spinal cord to from a dorsal hemisection. The
injury site was covered with a piece of artificial dura and the back muscles closed using
degradable sutures. Finally the skin was stapled close and the animals were treated with
buprenorphine.
Two weeks following the initial incision, the injury site was re-exposed and the
scar tissue removed from the spinal cord to create a cavity for scaffold implantation.
Fibrin scaffolds were prepared by mixing 10 mg/ml fibrinogen, 2.5 mM CaCl2 (Sigma),
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2 NIH units/ml thrombin (Sigma), 62.5 μM heparin, 0.25 mM AT-III peptide, 125 ng
NT3, and 125 ng GDNF or 20 ng PDGF per scaffold (NT3 + GDNF and NT3 +
PDGF groups). For fibrin control groups (Fibrin), the following components were
omitted: heparin, AT-III peptide, NT3, GDNF, PDGF. For delivery system (DS)
control groups all growth factors were omitted. A 10 μl fibrin scaffold with 10 EBs
containing pMNs embedded at the center of the scaffold was allowed to polymerize
fully for 5 minutes prior to implantation into the injury site. Following implantation, a
second 10 μl fibrin scaffold consisting of 10 mg/ml fibrinogen, 2.5 mM CaCl2 (Sigma),
and 2 NIH units/ml thrombin was allowed to polymerize in situ to hold the scaffold
containing EBs within the injury site. The implantation site was then covered with
artificial dura, the overlying back muscle closed using degradable sutures, and the skin
stapled close.
Immediately following each surgery, animals were given cefazolin (25 mg/kg)
and buprenorphine (0.04 mg/kg). Cefazolin was continued twice daily for 5 days with
carprofen tablets. Bladders were manually expressed twice a day for the entire study.
Following the second surgery, immune suppression was accomplished by daily
injections of cyclosporine-A (10 mg/kg) to reduce immune rejection of mouse cells.
Two weeks following cell transplantation, animals were euthanized by an overdose of
Euthasol. Spinal cords were harvested following transcardial perfusion with 4%
paraformaldehyde and post-fixed in 4% paraformaldehyde overnight. The following
day, spinal cords were cryoprotected by immersion in 30% sucrose in PBS. Prior to
embedding, 2 cm sections of the spinal cords with the injury site in the center were cut
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and frozen on dry ice. Cords were embedded in Tissue-Tek OCT compound and cut
into 20 μm sagittal sections with a cryostat.

3.3.6 Immunocytochemistry
Immunohistochemistry was used to assess the expression of markers of
differentiation for transplanted pMNs. OCT was washed from sections with PBS.
Sections were permeabilized with 0.1% triton X-100 for 15 minutes and blocked with
10% bovine serum albumin and 2% normal goat serum (NGS). The following primary
antibodies were applied overnight at 4˚C in 2% NGS in PBS: β-tubulin III (β-tubIII,
Covance, 1:400), choline acetyltransferase (ChAT, 1:500), oligodendrocyte marker 4
(O4, 1:500), glial fibrillary acidic protein (GFAP, 1:50), neuronal nuclei (NeuN, 1:500),
and nestin (1:25). Primary antibody staining was followed by 3 washes with PBS.
Appropriate Alexa Fluor secondary antibodies (Invitrogen) in 2% NGS in PBS were
applied for 1 hour at room temperature followed by an additional 3 washes in PBS. Cell
nuclei were stained with the nuclei binding dye DAPI (1:1000). Sections were mounted
using FluorMount (Invitrogen).

3.3.7 Image Analysis of Differentiation Markers
To quantify the staining of differentiation markers on transplanted EBs
containing pMNs, every twentieth section from each spinal cord was analyzed. A series
of 100x images spanning the lesion site were captured using a MICROfire camera
attached to an Olympus IX70 inverted microscope. GFP+ pixels were identified in each
image and the total area of GFP+ pixels counted per image using a custom Matlab
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program (Matlab, Appendix A). Fluorescent staining for one of the six markers of
differentiation (Nestin, βtubIII, GFAP, O4, NeuN, and ChAT) was assessed in each of
the GFP+ pixels to determine a total area of staining using the same program. In
addition, nuclei counts were performed within GFP+ areas to determine the total
number of GFP+ cells in each image (Figure 3.1).

3.3.8 Statistical Analysis
Statistical significance was determined by one way analysis of variance
(ANOVA) using Statistica Software (Statistica). Statistical significance was set at p <
0.05. For in vitro experiments, a Tukey’s HSD test was used to determine significance
(p<0.05). Statistical significance for in vivo studies was determined by the planned
comparisons post-hoc test (p<0.05).

3.4 Results
3.4.1 High Purity pMNs Survive and Differentiate in Fibrin Scaffolds

In Vitro
To determine the survival and differentiation of high-purity pMNs in fibrin
scaffolds, EBs containing pMNs were selected with puromycin to remove undesired
cells and encapsulated in either unmodified fibrin scaffolds (Fibrin group) or fibrin
scaffolds containing the following delivery system components: heparin and AT-III
peptide (DS); heparin, NT3, and PDGF (Hep + NT3 + PDGF); heparin, NT3, and
GDNF (Hep + NT3 + GDNF); heparin, AT-III, NT3, and PDGF (DS + NT3 +
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PDGF); or heparin, AT-III, NT3, and GDNF (DS + NT3 + GDNF). The same fibrin
scaffold conditions were repeated for selection control (unselected) groups where EBs
containing pMNs were not selected with puromycin. In both selected and unselected
groups, axons and cells migrated from EBs (Figure 3.1). Bright GFP fluorescence was
observed in encapsulated cells (Figure 3.1).

Figure 3.1 Cell survival and migartion following a two week in vitro culture within fibrin
scaffolds. Phase contrast (left) image of an encapsulated EB with cell migration into the fibrin
gel. GFP expression (right) in cells contained within the EB and in cells migrating out of the
EB. Scale bar = 100 µm.

To characterize the percentage of cells differentiating into astrocytes, oligodendrocytes,
neurons, and motoneurons, flow cytometry was performed following the two week in
vitro culture period in fibrin scaffolds. Two different combinations of growth factors
were tested (NT3+GDNF and NT3+PDGF). The percentage of cells labeling with
ChAT (motoneurons) was unchanged in selected and unselected groups for all of the
fibrin scaffold conditions tested (Figure 3.2).
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Figure 3.2 Flow cytometry analysis of pMN differentiation following a two week in vitro
culture within fibrin scaffolds with (A) NT3 and GDNF growth factors and (B) NT3 and
PDGF growth factors. Cell markers include O4 (oligodendrocytes), GFAP (astrocytes),
NeuN (neurons), and ChAT (motoneurons). * indicates p < 0.05. Abbreviations:
oligodendrocyte marker 4 (O4), glial fibrillary acidic protein (GFAP), neuronal nuclei (NeuN),
choline acetyltransferase (ChAT), delivery system (DS), heparin (Hep), neurotrophin-3 (NT3),
glia-derived neurotrophic factor (GDNF), platelet derived growth factor (PDGF).
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A significant decrease in the number of NeuN+ neurons was observed in the Hep +
NT3 + GDNF selected group and the DS + NT3 + GDNF unselected group
compared to the DS selected group and the Fibrin unselected group. Overall the
percentage of NeuN+ neurons and ChAT+ motoneurons was low (<10%) in all groups.
A significant decrease in GFAP (astrocytes) staining was observed in the DS + NT3 +
GDNF group compared to the Fibrin unselected and selected groups as well as the DS
unselected group. The percentage of GFAP+ cells also decreased in the selected
DS+NT3+PDGF group versus the selected fibrin group. The addition of growth
factors appeared to decrease differentiation into astrocytes. Finally, significantly greater
O4 (oligodendrocytes) labeling was observed in the DS + NT3 + GDNF selected
condition compared to the DS + NT3 + GDNF unselected condition. In general,
oligodendrocyte differentiation appeared to decrease with growth factor addition in the
unselected control groups while the presence of growth factors appeared to improve
oligodendrocyte differentiation in selected groups.

3.4.2 High Purity pMNs Survive and Migrate in a Sub-acute Dorsal
Hemisection Injury
The ability of high purity ES cell-derived populations to survive when
transplanted in the injured spinal cord has yet to be determined. To investigate the
ability for high purity pMNs to survive when encapsulated in fibrin scaffolds we
examined cell survival two weeks post-transplantation into a sub-acute dorsal
hemisection SCI. Furthermore, the impact of growth factor delivery using an affinitybased delivery system on cell survival was assessed. P-Olig2 cells contained
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ubiquitously expressed GFP under the β-actin promoterto facilitate visualization of
transplanted cells. Four fibrin conditions were assessed: fibrin alone (Fibrin), fibrin
scaffolds incorporating the affinity based delivery system (DS), fibrin scaffolds with DS,
NT3, and GDNF (DS+NT3+GDNF), and fibrin scaffolds with the DS, NT3, and
PDGF (DS+NT3+PDGF). Two weeks following transplantation, spinal cords were
harvested and the area of GFP expression was determined. GFP+ cells were observed
in the lesion cavity of all animals (Figure 3.3A). In some cases, migration of GFP+ cells
into the spinal cord was observed (Figure 3.3B). No significant differences in the total
GFP+ area were found between any of the fibrin conditions (Figure 3.4A). The total
cell count as assessed by nuclei labeling with DAPI within GFP+ areas was similar
between groups (Figure 3.4B). High purity pMNs survive and in some cases, appear to
integrate into the injured spinal cord. Over-proliferation was not induced by the
addition of growth factors as observed in previous studies.

3.4.3 Differentiation of Transplanted pMNs following SCI
To determine the ability for enriched pMNs to differentiate within fibrin
scaffolds following transplantation into the injured cord, expression of cell-type specific
markers were analyzed by immunohistochemistry two weeks post-transplantation into
the sub-acute dorsal hemisection SCI. The area of 6 markers of differentiation (nestin,
neural progenitors; neurons, βtubIII; astrocytes, GFAP; oligodendrocytes, O4;
motoneurons, ChAT) that co-labeled with GFP was quantified for each animal (Figure
3.5). Nestin expression was low in all groups suggesting that cells had differentiated
into mature cell types. The area of nestin expression was significantly decreased in the
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Figure 3.3 Immunohistochemistry of the injured spinal cord two weeks post-transplantation
of pMNs in the DS+HEP+NT3+PDGF group (A) Compiled overview of the dorsal
hemisection injury site containing transplanted cells (GFP). Astrocytes are labeled with
GFAP. (B) Magnified inset of the transplant host border. Scale bar = 500 µm.
Abbreviations: glial fibrillary acidic protein (GFAP), green fluorescent protein (GFP).

DS+NT3+PDGF group compared to the Fibrin group. βtubIII and NeuN labeling
was observed in all groups, demonstrating successful differentiation into neuronal subtypes. No significant differences in βtubIII expression were found between any groups,
however, NeuN+ area was shown to be statistically greater in the DS group compared to
both the DS+NT3+PDGF and the DS+NT3+GDNF group. Both astrocytes
(GFAP) and oligodendrocytes (O4) were observed in all groups. No statistical
differences were observed in O4+ areas between all groups. The area of GFAP
expression was statistically lower in the DS+NT3+GDNF group compared to the
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Fibrin alone group. Successful differentiation into motoneurons was observed in every
group as evidenced by ChAT expression. ChAT labeling followed a similar expression
pattern to βtubIII. High purity pMN populations not only survive in the injured cord,
but differentiate into the proper cell types including oligodendrocytes, astrocytes, and
motoneurons.

3.5 Discussion
Differentiation of ES cells is often limited by low efficiencies. Heterogeneous
transplant populations can contain undesired cell types that confound results and in
some cases, lead to tumor formation. We have previously demonstrated antibiotic
selection as a viable method for purification of ES cell-derived pMNs. In this study, we
demonstrated that high purity pMN populations survive and differentiate into the
appropriate cell types within tissue engineered fibrin scaffolds in vitro and within the
injured cord. Furthermore, neuronal differentiation did not appear to be inhibited as
commonly reported following transplantation into SCI environment.
Tissue-engineered fibrin scaffolds promoted subtle changes in differentiation of
control unselected pMN cultures and highly enriched pMN cultures after a two week
culture in vitro. The addition of growth factors appeared to increase differentiation into
the oligodendrocytes fate for high purity pMNs though no statistical differences were
observed. This effect was not observed in control cultures. Statistical difference was
observed in between control and selected DS+NT3+GDNF groups. This may be due
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Figure 3.4 Analysis of transplant cell survival within the injured spinal cord after two weeks.
(A) Average total area of GFP expression in each transplant group (B) Average nuclei counts
within GFP-positive areas. No significant differences were observed. Abbreviations: delivery
system (DS), heparin (Hep), neurotrophin-3 (NT3), glia-derived neurotrophic factor
(GDNF), platelet derived growth factor (PDGF).
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to removal of confounding cell types that may respond similarly to NT3 and GDNF or
that secrete factors inhibiting oligodendrocytes differentiation. In general, percentage of
astrocytes appeared to decrease in both cell groups with the addition of growth factors,
though statistical differences were not consistent. During the two week culture, axons
from EBs containing pMNs extended through the fibrin scaffolds. Oligodendrocytes
migrated out in the scaffold away from the EB. GFP expression was maintained
during the two week period and suggested survival of the encapsulated cells. Antibiotic
selection improved the differentiation of ES cell-derived populations into
oligodendrocytes within tissue engineered fibrin scaffolds.
High purity pMN transplants survived in the injured spinal cord and
differentiate into appropriate mature cell types (neurons, oligodendrocytes and
astrocytes). The presence of growth factors did not appear to influence survival or
proliferation of transplanted cells contrary to results previously obtained from
heterogeneous transplant populations that show greater cell numbers two weeks after
transplantation. These results suggest the absence of tumor forming cell types such as
undifferentiated ES cells. In many instances, cells migrated from the graft into host
tissue. This may be enhanced by the lack of robust glial scarring. These results suggest
that high purity pMNs differentiate into appropriate spinal cell types capable of
integrating with the host spinal tissue. Indeed, transplanted cells differentiation into
spinal motoneurons, oligodendrocytes and astrocytes as observed in vitro. Neuronal
differentiation was observed in all grafts though greatest expression was observed in the
DS group. This may be due to sequestering of growth factors expressed in the injury
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Figure 3.5 Immunohistochemical analysis of transplant cell differentiation within the injured
spinal cord after two weeks. (A) Average area of nestin (neural progenitors) expression. (B)
Average area of βtubIII (immature neurons) expression. (C) Average area of NeuN (mature
neurons) expression. (D) Average area of ChAT (motoneurons) expression. (E) Average area
of GFAP (astrocytes) expression. (F) Average area of O4 (oligodendrocytes) expression. *
indicates p < 0.05. Abbreviations: β-tubulin class III (βtubIII), oligodendrocyte marker 4
(O4), glial fibrillary acidic protein (GFAP), neuronal nuclei (NeuN), choline acetyltransferase
(ChAT), delivery system (DS), heparin (Hep), neurotrophin-3 (NT3), glia-derived
neurotrophic factor (GDNF), platelet derived growth factor (PDGF).
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site by unoccupied heparin sites present in the scaffold. Similar to in vitro studies, the
NT3 + GDNF growth factor combination reduced astrocyte differentiation. These
results suggest that in vitro studies may be able to approximate in vivo results, at least in
the case of high purity pMNs. Transgenic enrichment of pMNs appears to generate a
promising cell transplant populations for treatment after SCI.
The development of high purity ES cell-derived transplant populations can
benefit cell replacement therapies for SCI. This study demonstrates the feasibility of
high purity pMN populations for repair of the injured cord. Future studies to elucidate
the effect of this cell population on functional recovery can further its therapeutic
application. Antibiotic selection appears to be a safe and effective mechanism for
improving ES cell-derived cell transplant populations.
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Chapter 4
Generation of High Purity Cholinergic Motoneurons
by Hb9-Enhancer Driven Antibiotic Resistance in
Genetically Engineered Mouse Embryonic Stem Cells
4.1 Abstract
Many techniques have been developed to isolate motoneurons from
heterogeneous cell populations; however, their utility for purification of embryonic stem
(ES) cell-derived motoneurons has not been fully developed. We engineered a
transgenic-ES cell line that allows antibiotic selection to purify motoneurons following
differentiation of mouse ES cells. Highly conserved enhancer elements for the
motoneuron transcription factor Hb9 were used to drive puromycin N-acetyltransferase
(PAC) expression in ES cell-derived motoneurons. Following puromycin selection,
high purity motoneuron cultures were obtained. Purity was maintained during
maturation to produce consistent, uniform populations of cholinergic ES cell-derived
motoneurons. Functional properties of purified motoneurons were examined by acetyl
cholinesterase (AChE) activity and electrophysiology. Puromycin-selected motoneurons
exhibited appropriate voltage-gated and ligand-gated ion channel activity with the ability
to fire multiple action potentials. Selected cultures were post-mitotic and did not
contain astrocytes or other proliferating glia frequently observed in ES cell-derived
motoneuron cultures. Antibiotic selection, therefore, can provide an inexpensive
alternative to current methods for isolating motoneurons at high purity that does not
require specialized laboratory equipment.
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4.2 Introduction
The ability to culture neurons in vitro has many advantages including
applications in toxicology screening, developmental studies, and cell replacement
strategies. ES cells hold great potential as an expandable cell source that can be
differentiated into specific neuronal sub-types by recapitulating developmental signals.
The signaling events necessary for differentiation of ES cells into midbrain
dopaminergic neurons (Lee et al., 2000), cortical pyramidal neurons (Gaspard et al.,
2009), cerebellar neurons (Salero and Hatten, 2007), dorsal interneurons (Murashov et
al., 2005), and spinal motoneurons (Wichterle et al., 2002) have been previously
described. ES cell-derived neurons have been shown to maintain neuronal sub-type
specific properties and have the potential to integrate when transplanted into
appropriate regions of the central nervous system (Kim et al., 2002, Wichterle et al.,
2009, Espuny-Camacho et al., 2013). Furthermore, transplanted mouse ES cell-derived
motoneurons have been shown to restore partial motor function following selective
ablation of host spinal motoneurons in rats (Deshpande et al., 2006).
The directed differentiation of ES cells into spinal motoneurons can be achieved
by exposure of embryoid bodies (EBs) to retinoic acid (RA) and sonic hedgehog (Shh)
(Wichterle and Peljto, 2008). RA serves as a caudalizing signal to generate spinal
progenitor cells, while Shh acts as a ventralizing agent to induce differentiation into
progenitor motoneurons (pMNs) expressing the basic helix-loop-helix transcription
factor Olig2. Spinal motoneurons differentiate from pMNs by expressing the
homeobox domain transcription factor Hb9 and down-regulating Olig2 (Arber et al.,
1999). In addition to motoneurons, pMNs also give rise to oligodendrocytes and
77

astrocytes in vitro (Xian and Gottlieb, 2004). The efficiency of differentiation into
pMNs can be enhanced by use of small molecule agonists of the Shh pathway, resulting
in up to up to 50% of the total cell population expressing Hb9 (Li et al., 2008). Postmitotic motoneurons, however, are diluted as a percentage of the total cell population
by the continuing proliferation of glia during extended culture. High purity mature
motoneuron cultures may be desired to evaluate neuron-glia interactions and to
maintain independent cultures, as well as for cell transplantation.
Several methods have been developed to purify motoneurons from mixed cell
cultures. Isolation of MNs from mouse (Gingras et al., 2007), rat (Schnaar and
Schaffner, 1981), and chick (Schnaar and Schaffner, 1981) fetal spinal cord has been
demonstrated using density gradient centrifugation to separate large motoneurons based
on cell density. While initially successful, this technique cannot guarantee removal of
glia. When applied to human and monkey ES cell-derived motoneurons, gradient
centrifugation provided partial enrichment of motoneurons (Wada et al., 2009). Purity
following extended culture of enriched human ES cell-derived motoneurons, however,
was not assessed. Alternatively, the Hb9 promoter has been used to drive enhanced
green fluorescent protein (eGFP) expression for visual identification and fluorescence
activated cell sorting (FACS) of ES cell-derived motoneurons (Singh Roy et al., 2005).
FACS, however, is time intensive and requires a central facility with expensive
equipment, and it also has the potential to contaminate cell cultures. Other methods
have been utilized to purify motoneurons, including panning for the low affinity nerve
growth factor receptor (p75), but these approaches may limited by specificity and
technical difficulty (Camu and Henderson, 1992).
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The development of a low-cost, reproducible technique for producing high
purity ES cell-derived motoneurons can provide a powerful tool to enable studies of
neurodegenerative diseases and development. In this study, we obtained high purity
cultures by antibiotic selection of ES cell-derived motoneurons. Mouse ES cells were
transfected with a selection vector containing two highly conserved enhancers of the
Hb9 gene driving the puromycin resistance enzyme, PAC. Following differentiation of
ES cells into motoneurons, addition of puromycin to the culture media killed cells not
expressing Hb9. Motoneuron purity was assessed immediately following puromycin
selection and was maintained through maturation cultures. High-purity motoneurons
matured into functional cholinergic neurons as determined by an AChE activity assay
and electrophysiology. This technique provides an inexpensive and scalable method for
obtaining high purity mature motoneuron cultures.

4.3 Materials and Methods
4.3.1 Embryonic Stem Cell Culture
Mouse ES cells were cultured on gelatin-coated T-25 flasks in complete media
consisting of Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies,
Carlsbad, CA) containing 10% newborn calf serum (Life Technologies), 10% fetal
bovine serum (Life Technologies), 10 μM thymidine (Sigma, St. Louis, MO), and 30 μM
of each of the following nucleosides (Sigma): adenosine, cytosine, guanosine, and
uridine. For routine culture, ES cells were passaged every two days. Briefly, ES cells
were washed with DMEM containing 25 mM HEPES (Life Technologies) and
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dissociated with 0.25% trypsin-EDTA (Life Technologies) for 5 min. Trypsin was
quenched with fresh complete media and cells were transferred to a new gelatin-coated
flask at a 1:5 ratio in fresh complete media containing 1000 U/mL leukemia inhibitory
factor (LIF; Millipore, Bellerica, MA) and 100 μM β-mercaptoethanol (BME; Life
Technologies).

4.3.2 Hb9-Puro Selection Vector
Hb9 enhancers A and B followed by the minimal β-globin promoter were PCR
amplified from the CSH2IV vector (kind gift from Patrick Blanner). The resulting PCR
product was cut and ligated into a vector containing the puromycin resistance cassette
(kind gift from David Gottlieb). The resistance cassette also contained the gene for a
neomycin resistance enzyme, neomycin phosphotransferase, driven by the ubiquitously
expressed phosphoglycerate kinase (PGK) promoter for identification of integration
events. The PGK promoter and the neomycin phosphotransferase gene were flanked
by loxP sites to facilitate removal following integration of the Hb9-Puro vector. Ligated
vector was amplified in DH5α E. Coli and isolated using a mini-prep kit (Qiagen,
Hilden, DE).

4.3.3 Electroporation and Cre Excision
RW4 ES cells were used to make a transgenic ES cell line. Approximately 10 x
106 ES cells were resuspended in electroporation buffer with 10 μg Sal1 linearized Hb9Puro selection vector. Cells were electroporated at 0.23 kV and 960 μF in a 0.4 cm
cuvette (Bio-Rad, Hercules, CA) and plated on 100 mm gelatin-coated petri dishes in
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complete media with 1000 U/mL LIF, 100 μM BME, and 40 ug/mL geneticin (Life
Technologies). Media was replaced every 2 days. After 9 days, single colonies were
picked and plated in individual wells of a gelatin-coated 48 well plate containing
complete media with 1000 U/mL LIF and 100 μM BME. Clones were screened for
puromycin resistance at the ES cell state and resistant clones were discarded. The
pTurboCre plasmid (kind gift from David Gottlieb) was used to remove the PGK
promoter and neomycin phosphotransferase gene from transgenic ES cells.
Approximately 3 ng plasmid was incubated in Opti-MEM media (Life Technologies)
and Lipofectamine 2000 (Life Technologies). Half of the culture media was replaced
with Opti-MEM media containing pTurboCre plasmid and Lipofectamine 2000 for 4
hours. Media was then replaced with complete media containing LIF and BME and
cells were allowed to recover overnight. The following day, ES cell cultures were
dissociated and plated at 6 x 103 cells/cm2 in individual wells of a gelatin-coated 6 well
plate in complete media with 1000 U/mL LIF, 100 μM BME, and 40 ug/mL geneticin.
After 9 days, single colonies were picked and plated in individual wells of a gelatincoated 48 well plate containing complete media with LIF and BME. Clones were
screened for sensitivity to neomycin by exposure to 40 µg/ml geneticin for 5 days, and
those that were not sensitive were discarded.

4.3.4 Motoneuron Differentiation
Transgenic ES cells were differentiated into motoneurons using a 2-/4+ RA and
smoothened agonist (SAG, Millipore) induction protocol as previously described
(McCreedy et al., 2012). Approximately 1 x 106 ES cells were cultured in suspension on
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agar-coated 100 mm petri dishes in modified DFK5 media consisting of DMEM/F12
base media (Life Technologies) containing 5% knockout serum replacement (Life
Technologies), 1x insulin transferrin selenium (ITS; Life Technologies), 50 μM
nonessential amino acids (Life Technologies), 100 μM β-mercaptoethanol, 5 μM
thymidine, and 15 μM of the following nucleosides: adenosine, cytosine, guanosine, and
uridine. During this process, ES cells aggregate into multi-cellular EBs. After the first
two days (2-), the EBs were moved to a 15 mL conical and allowed to settle for 5 min.
The media was aspirated and replaced with 10 mL fresh DFK5 containing 2 μM RA
and 600 nM SAG. In differentiated control cultures, the Shh antagonist cyclopamine
(Cyc, 1 μM; Sigma) was used instead of SAG. EBs were then cultured for an additional
4 days (4+), and media was replaced every 2 days.

4.3.5 Motoneuron Selection
Transgenic ES cells differentiated using the 2-/4+ RA and SAG induction were
dissociated in 0.25% Trypsin-EDTA for 15 minutes and quenched with complete
media. Dissociated cells were counted and centrifuged at 240 x g for 5 minutes. Cells
were resuspended in DFK5 media containing 5 ng/mL glial-derived neurotrophic factor
(GDNF; Peprotech, Rocky Hill, NJ), 5 ng/mL brain derived neurotrophic factor
(BDNF; Peprotech, Rocky Hill, NJ), 5 ng/mL neurotrophin-3 (NT-3; Peprotech, Rocky
Hill, NJ), 4 μg/mL puromycin in water (Sigma) and plated at 6 x 104 cells/cm2 in
individual wells of a laminin-coated 6 well plate for 24 hours. In parallel control
cultures not receiving puromycin, cells were resuspended in DFK5 media with the
growth factor cocktail and plated at 3 x 104 cells/cm2 in individual wells of a laminin82

coated 6 well plate for 24 hours. Following selection, cells were fixed for
immunofluorescence or media was replaced with modified DFKNB media consisting of
DFK5 and Neural basal (NB) media (Life Technologies) mixed at a 1:1 ratio and
supplemented with B27, 5 ng/mL GDNF, 5 ng/mL BDNF, and 5 ng/mL NT-3. Cells
were cultured in DFKNB media for up to 8 additional days.

4.3.6 Polymerase Chain Reaction
Cell lysates were collected using an RNeasy kit (Qiagen) from ES cells, ES cells
differentiated with the 2-/4+ RA and SAG or the 2-/4+ RA and Cyc induction protocol.
50 ng mRNA from each sample was amplified using a One-Step PCR Kit (Qiagen).
Primers for Hb9 were as follows: 5’-GGCCATAGGATGGGATTGTA-3’(forward), 5’CGGCGCTTCCTACTCATAC-3’(reverse).

4.3.7 Cell Viability Assay
To determine cell viability after puromycin selection, ES cells were differentiated
using the 2-/4+ RA and SAG or the control 2-/4+ RA and Cyc induction protocol.
Differentiated cells and undifferentiated ES cells were dissociated and plated in
individual wells of laminin-coated 6 well plate in DFK5 media with 4 μg/mL puromycin
at a density of 6 x 104 cells/cm2 and 4 x 104 cells/cm2, respectively. Cells were selected
with puromycin for 24 hours. Control cultures not receiving puromycin were run in
parallel. Following puromycin selection, media was replaced with fresh DFK5
containing calcein-AM (Life Technologies) for 30 minutes. Fluorescent images were
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captured using a MICROfire camera attached to an Olympus IX70 inverted
microscope.

4.3.8 Transcription Factor Analysis
Due to the short temporal expression of the Olig2 and Hb9 transcription
factors, ES cells were differentiated using a modified 2-/4+ RA and SAG exposure
protocol, where EBs were dissociated at 2-/3+ and plated in individual wells of a
laminin-coated 6-well plates in fresh DFK5 media containing 2 μm RA, 600 nM SAG,
and 2 ug/mL puromycin for 20 hours prior to fixation for immunofluorescence.
Control cultures without puromycin for the 20 hour selection period were run in
parallel. Culture were fixed following selection and analyzed by immunofluorescence
(see Immunofluorescence and Cell Counting).

4.3.9 Immunofluorescence and Cell Counting
Cells were fixed in 4% (w/v) paraformaldehyde (Sigma) in phosphate buffered
saline (PBS) for 15 minutes at room temperature. Fixed cultures were washed once
with PBS, and the cells were permeabilized with 0.1% triton-X in PBS for 15 minutes.
Cultures were then blocked for 1 hour at 4°C with 5% normal goat serum (NGS;
Sigma) in PBS. Primary antibodies were added to blocked cultures overnight at 4°C at
the following dilutions in 2% NGS in PBS: neurofilament (NF, 1:50, Iowa
Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA), Olig2 (1:400,
Millipore), MNR2/Hb9 (1:20, DSHB), β-tubulin III (β-TubIII, 1:400, Millipore),
choline acetyltransferase (ChAT, Millipore), ChAT (ChAT4B, DSHB), or glial fibrillary
84

acidic protein (GFAP, 1:100, ImmunoStar, Hudson, WI). Primary antibodies were
labeled with the appropriate AlexaFluor conjugated goat antibodies (Life Technologies)
at a 1:200 dilution in 2% NGS in PBS for 4 hours. All wells were counterstained with
the Hoechst (1:1000; Life Technologies) to label cell nuclei. Following
immunofluorescence, phase contrast and fluorescent images were captured. Live cells
were identified by phase contrast and Hoechst staining. Cells with apparent processes
and round nuclei were included in the cell counting experiments. Cells with fragmented
nuclei demonstrating evidence of cell death were not included in total cell counts. Cell
counting was performed using ImageJ software.

4.3.10 AChE Staining
A modified Karnovsky stain was used to assess AChE activity in motoneurons.
Cells were washed with PBS and fixed in 4% paraformaldehyde in PBS for 30 minutes.
The wells were washed with water and incubated in AChE staining solution consisting
of 65mM phosphate buffer (pH = 6.0; Sigma), 10 mg/mL gelatin (Sigma), 5 mM
sodium citrate (Sigma), 3 mM copper sulfate (Sigma), 0.5 mM potassium ferricyanide
(Sigma), 0.2 mM ethropropazine (Sigma) and 4 mM acetylthiocholine (Sigma) for 7
days. Wells were rinse 5 times with water. Water was removed and Prolong Gold
mounting solution containing DAPI (Life Technologies) was added to each well. A
coverslip was carefully placed over the well and mounting solution was allowed to
harden overnight at room temperature. Brightfield images and fluorescent images were
taken the following day.
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4.3.11 Electrophysiology
Cultures were bath perfused with Tyrode’s solution (in mM): 150 NaCl, 4 KCl, 2
MgCl2, 2 CaCl2, 10 glucose, 10 HEPES, pH adjusted to 7.4 with NaOH. Whole-cell
electrodes pulled from borosilicate glass capillaries had an open tip resistance of 2 to 5
MOhm when filled with one of the following internal solutions (in mM): (1) 140 Kglucuronate, 10 NaCl, 5 MgCl2, 0.2 EGTA, 5 Na-ATP, 1 Na-GTP, 10 HEPES, pH
adjusted to 7.4 with KOH; (2) 140 Cs-glucuronate, 5 CsCl, 5 MgCl2, 10 EGTA, 5 NaATP, 1 Na-GTP, 10 HEPES, pH adjusted to 7.4 with CsOH; or, (3) 120
tetraethylammonium (TEA) chloride, 5 MgCl2, 5 Na-ATP, 1 Na-GTP, 10 EGTA, 10
HEPES, pH adjusted to 7.4 with TEA-hydroxide. Current and voltage were recorded
with an Axopatch 200A amplifier, filtered at 1 kHz, digitized at 10 kHz and analyzed
off-line with Clampfit software (pClamp 9.2). Voltage-gated channel antagonists
tetrodotoxin (TTX) and 4-aminopyridine (4-AP) were dissolved in Tyrode’s solution
and delivered under gravity flow from a local perfusion pipette (Kim et al., 2009).
Ligand-gated channel agonists were dissolved in 160 NaCl, 10 HEPES, 2 CaCl2 and also
applied by local perfusion.

4.3.12 Statistical Analysis
Unless otherwise noted all measured parameters are reported as mean +/- SEM.
Statistical significance was determined by Scheffe’s post hoc test for analysis of variance
(ANOVA) using Statistica software (version 5.5; StatSoft, Tulsa, OK). Significance was
assigned for P values less than 0.05.
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4.4 Results
4.4.1 Hb9 Enhancers Drive Puromycin Resistance Following
Differentiation of Embryonic Stem Cells into Motoneurons
Differentiation of ES cells using RA and Shh gives rise to multiple cell types
(Figure 4.1). To isolate motoneurons from the diverse cell population, we developed a
new selection vector (Hb9-Puro) containing previously identified enhancer elements of
the motoneuron transcription factor, Hb9, driving the puromycin resistance enzyme,
PAC (Figure 4.2A) (Nakano et al., 2005). The Hb9-Puro selection vector was
electroporated into ES cells, and the resulting cultures were screened for neomycin
resistance to ensure genomic incorporation of the vector. Transgenic ES cells were then
treated with cre recombinase to remove the neomycin selection cassette that is flanked
by loxP sites. The transgenic ES cell cultures were aggregated for two days (2-) to form
EBs as part of a 2-/4+ induction protocol. EBs were exposed to RA and SAG, for four
days (4+) to induce differentiation into motoneurons. Undifferentiated ES cells and ES
cells differentiated with RA and the Shh antagonist, Cyc were used as controls. Cells
from each group were lysed and presence of Hb9 mRNA was assessed by RT-PCR. In
cultures receiving RA and SAG, Hb9 mRNA was detected by PCR (Figure 4.2B). No
Hb9 mRNA was observed in either control group.
To determine if Hb9 expression led to expression of PAC, cultures
differentiated with RA and SAG were dissociated following the 2-/4+ induction
protocol and plated on laminin-coated wells with puromycin (4 μg/mL) in the media
for 24 hours. Parallel cultures not receiving puromycin, as well as undifferentiated ES
cells and ES cells differentiated with RA and Cyc, were used as controls. In the absence
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Figure 4.1 Motoneuron differentiation of ES cells following RA and Shh induction.
Following the 2-/4+ induction protocol, ES cells differentiate into tri-potent pMNs. The
resulting pMNs can differentiate into motoneurons, astrocytes, or oligodendrocytes. Markers
for each cell type are shown in gray.

of puromycin, all cultures contained viable cells as evidenced by calcien AM staining
(Figure 4.2C). With puromycin, undifferentiated ES cells and ES cells differentiated
with RA and Cyc did not survive. Viable cells, however, were present following
puromycin selection for ES cells differentiated with RA and SAG. Surviving cells
displayed phase bright cell bodies and long neurites, morphology consistent with
neuronal differentiation.

4.4.2 Surviving Cells Label for Immature Motoneuron Markers
Immediately Following Puromycin Selection
To determine if Hb9 enhancer-driven puromycin resistance was specific to
motoneurons, we investigated the expression of Olig2 and Hb9, two transcription
factors associated with motoneuron development and differentiation. Due to the short
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Figure 4.2 Hb9-Puro selection vector and puromycin resistance. (A) Schematic showing
location of Hb9 enhancers A and B upstream of Hb9 gene. Enhancers A and B were used in
conjunction with the minimal β -globin promoter (β) to drive PAC expression. Neomycin
phosphotransferase expression was driven by the ubiquitously expressed PGK promoter for
identification of cells with incorporated vector. Cre recombinase was used to remove the
PGK promoter and neomycin phosphotransferase gene following incorporation into ES cells.
(B) Hb9 mRNA expression in ES cells (ES), ES cells differentiated with RA and Cyc (Cyc),
and ES cells differentiated with RA and SAG (SAG). (C) Live cell assay in ES cells, ES cells
differentiated with RA and Cyc (Cyc), and ES cells differentiated with RA and SAG (SAG)
following puromycin selection. Control cultures were run in parallel without puromycin.
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temporal expression of Olig2 and Hb9, a modified 2-/4+ induction and selection
protocol was used. ES cells were aggregated for two days into EBs and exposed to RA
and SAG for three days (2-/3+). EBs were then dissociated and plated on laminincoated plates with puromycin, RA, and SAG for 20 hours (Figure 4.3A). In parallel
cultures not receiving puromycin,, 32.3 ± 1.7% of cells stained positive for the pMN
transcription factor Olig2 and 46.3 ± 1.0% of cells stained positive for motoneuron
transcription factor Hb9 (Figure 4.3B-C). When puromycin was added during the 20 hr
selection period, no cells labeled for Olig2 (n=3, p<0.001) while 98.3 ± 0.10% of cells
were positive for Hb9 (n=3, p<0.001). Remaining viable cells had a consistent neuronal
morphology.
To increase the number of surviving cells for analysis of the neuron-specific
marker β-tubulin class III (β-tubIII), ES cells were aggregated for 2 days then exposed
to RA and SAG for 4 days (2-/4+), at which time Hb9 expression peaks. EBs were
then dissociated and plated on laminin-coated wells for 24 hours with puromycin
(Figure 4.4A). In parallel control cultures without puromycin, many cells were observed
with glial morphology and did not express β-tubIII (Figure 4.4B). Approximately 59.7 ±
2.79% of cells stained positive for β-tubIII at the end of the 24 hour period in control
cultures without puromycin selection. In cultures receiving puromycin for 24 hours,
cells with glial morphology were not observed. The percentage of cells expressing βtubIII significantly increased to 98.9 ± 0.20% following puromycin selection (n=3,
p<0.001, Figure 4.4C). The remaining viable cells also predominantly express the
neuronal marker MAP-2 (Figure 4.5).
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Figure 4.3 Puromycin selection of transgenic ES cells. (A) Schematic of modified 2-/4+
induction protocol including the 20-hour puromycin selection. Puromycin was added for 20
hours between day 5 and day 6. (B) Immunofluorescence analysis of Olig2 and Hb9
transcription factors following puromycin selection in culture not receiving puromycin
(control) and selected with 4 ug/mL puromycin (puromycin). (C) Counting analysis of control
and puromycin selected cultures. * indicates p < 0.001 for each marker compared to control
group. Scale bars = 100 µM.
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4.4.3 High Purity Motoneurons Achieve Functional Maturation
To determine if immature motoneurons could achieve functional maturation
following puromycin selection, ES cells were differentiated using the 2-/4+ RA and Shh
induction protocol and selected with puromycin for 24 hours on laminin-coated wells.
Cultures without puromycin were run in parallel. Following selection, cultures were
switched to DFKNB media without puromycin for 5 days prior to fixation (Figure
4.6A). In selected cultures, cells displayed large neuronal cell bodies and long branching
neurites, morphology typical of mature motoneurons. When labeled for the mature
neuronal marker neurofilament (NF), 99.4 ± 0.61% of cells were NF-positive in
selected cultures while only 5.42 ± 1.24% of cells expressed NF in control cultures not
receiving puromycin (n=3, p<0.001, Figure 4.6B). Large NF+ neurites were observed
extending between cell bodies of neurons in both cultures (Figure 4.6C).
Mature motoneurons contain AChE and choline acetyl-transferase (ChAT)
enzymatic activity. Poor staining of ChAT antibodies by immunofluorescence in vitro
has been previously reported (Bohl et al., 2008). Karnovsky staining has been utilized to
differentially label motor nerves from sensory nerves via AChE activity (Kanaya et al.,
1991). Similar assays have been used to label motoneurons in culture where antibodies
for ChAT were inconclusive. We employed a modified version of the Karnovsky stain
to assess AChE activity in fixed cultures (Gruber and Zenker, 1973, Kanaya et al., 1991,
Bohl et al., 2008). In this process the enzymatic activity of AChE facilitates a chemical
reaction resulting in Hatchett’s Brown precipitate. In control cultures, precipitate was
observed in cells with neuronal morphology (Figure 4.6c). Labeled cells accounted
for30.6 ± 1.67% of cells in the absence of puromycin. Significantly more cells, 99.3 ±
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Figure 4.4 Puromycin selection of transgenic ES cells. (A) Schematic of 2-/4+ induction
protocol followed by a 24-hour puromycin selection. Puromycin was added for 24 hours
between day 6 and day 7. (B) Immunofluorescence analysis of β-tubulin class III (β-tubIII)
following puromycin selection. (C) Counting analysis of control and puromycin selected
cultures. * indicates p < 0.001 for each marker compared to control group. Scale bars = 100
µM.
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Figure 4.5 Immunofluorescence staining of addition neuronal and motoneuron-associated
markers. MAP2 staining following the 2-/4+ induction protocol with a 24-hour puromycin
selection in control (left) and selected (right) cultures.

0.43% (n=3, p<0.001), contained precipitate in selected cultures and all cells displayed
neuronal morphology (Figure 4.6B-C). Cultures were also stained with two separate
ChAT antibodies (Figure 4.7). Bright fluorescence was observed in control and selected
cultures. In control cultures, dim non-specific staining was observed in cells with glial
morphology preventing accurate assessment of cell purity. Non-specific staining was
not observed in selected cultures.

4.4.4 Selected Cultures Are Post-Mitotic and Maintain Purity after
Extended Maturation
Neural differentiation of ES cells results in many glial sub-types that rapidly
proliferate and reduce neuronal purity. Astrocytes are one of the first mature glial cells
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to differentiate from glial progenitors. To evaluate the presence of astrocytes, cultures
were allowed to mature for 7 days following puromycin section (Figure 4.8A). Cultures
were then fixed and labeled for glial fibrillary acidic protein (GFAP). In control
cultures not receiving puromycin, GFAP+ astrocytes were frequently observed (Figure
4.8B). No GFAP labeling, however, was observed in any cultures receiving puromycin
for 24 hours. Cells in selected cultures maintained neuronal morphology with large cells
bodies and branched neurites.
Motoneurons are post-mitotic and will not proliferate like their glial
counterparts. To assess proliferation, ES cells were differentiated using the 2-/4+ RA
and SAG protocol and plated on laminin-coated-wells for 24 hours with puromycin in
the culture media. Control cultures without puromycin were run in parallel. The total
number of cell nuclei was assessed immediately following selection, at 3 days, and at 5
days post-selection. Control cultures contained approximately 29.6 x 103 cells/cm2,
while selected cultures contained approximately 9.3 x 103 cells/cm2 post-selection. The
number of cells in control cultures increased to 82.7 x 103 cells/cm2 and 147.8 x 103
cells/cm2 at 3 and 5 days after the selection period, respectively. Normalized to the
first day following selection, there was approximately a 2.8-fold and 5-fold increase in
cells for control cultures not receiving puromycin (Figure 4.8C). A decrease in cell
number was observed in selected cultures to 6.4 x 103 cells/cm2 (0.68 fold change) and
5.8 x 103 cells/cm2 (0.62 fold change) at 3 and 5 days post-selection suggesting that
proliferating cells were absent. The fold changes in control and selected cultures were
significantly different at 3 and 5 days post selection (n=3, p<0.05).
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Figure 4.6 Maturation of puromycin selected motoneurons. (A) Schematic of 2-/4+ induction
protocol followed by a 24-hour puromycin selection and 5 day extended culture. Puromycin
was added for 24 hours between day 6 and day 7. Media was replaced with DFKNB media
immediately following selection and cultures were continued for an additional 5 days (B)
Counting analysis of control and puromycin selected cultures for neurofilament (NF) marker
and acetylcholinesterase (AChE) assay. (C) Immunofluorescence analysis of NF and AChE
following 5 day extended culture. * indicates p < 0.001 for each marker compared to control
group. Scale bars = 100 µM.

4.4.5 Selected Cultures Maintain Mature Electrophysiological
Properties
To determine whether our puromycin selection process had any detrimental effects on
the ability of ES cell-derived motoneurons to undergo functional differentiation, we
performed whole-cell current- and voltage-clamp recordings between 0 and 7 days
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Figure 4.7 Immunofluorescence staining of addition neuronal and motoneuron-associated
markers. Immunofluorescence staining using two separate ChAT antibodies in control (left)
and selected (right) cultures following 2-/4+ induction protocol with a 24-hour puromycin
selection and 5 day extended culture period.

after puromycin selection (d0 to d7). When stimulated by depolarizing current injection,
cells recorded under current clamp at d2 to d7 fired action potentials (Figure 6A) with a
mean threshold of -34.1 ± 1.5 mV (n=19). More than half of the cells maintained a
negative resting membrane potential (< -50mV) without the need for DC
hyperpolarization. The average resting membrane potential (Vrest) in these cells was -60.4
± 1.2 mV (n=10). For long duration current pulses (800 msec) roughly one third of the
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cells only fired single action potentials, another third fired multiple spikes, but with low
frequency (10-15 Hz) and substantial adaptation in spike amplitude, while the remaining
cells fired repeatedly at 20-25 Hz and with much less spike amplitude adaptation (Figure
4.9A, Figure 4.10).
Under voltage-clamp, steps from a holding potential of -80 mV to more
depolarized test potentials evoked fast transient inward currents (Figure 4.9B) that were
blocked by the sodium channel antagonist tetrodotoxin (TTX); and, more slowly
activating, and partially inactivating, outward currents (Figure 4.9C) that were largely
eliminated when potassium in the internal solution was substituted with cesium (Cs) or
tetraethylammonium (TEA). In addition, the transient component of outward current
was selectively inhibited by holding at -40 mV or by extracellular exposure to 5 mM 4aminopyridine (4-AP)(Figure 4.9C). Lower doses of 4-AP (500 µM), which selectively
block transient outward current in some cell types (Bean, 2007), had minimal effect on
currents recorded in our puromycin-selected motoneurons (n=6). In addition to
voltage-gated sodium and potassium currents, the selected motoneurons also displayed
cadmium-sensitive currents mediated by voltage-gated calcium channels (Figure 4.9D),
which were recorded using 5 or 25 mM barium as the charge carrier and with both
internal and external monovalent cations largely replaced by TEA. Table 1 summarizes
parameters in the puromycin-selected motoneurons for activation and steady-state
inactivation of voltage-gated sodium and transient potassium currents, as well as
activation parameters for sustained potassium and calcium currents (Figure 4.11).
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Figure 4.8 Glial differentiation and proliferation following puromycin selection. (A)
Schematic of 2-/4+ induction protocol followed by a 24-hour puromycin selection and 7 day
extended culture. Puromycin was added for 24 hours between day 6 and day 7. Media was
replaced with maturation media immediately following selection and cultures were continued
for an additional 7 days (B) Immunofluorescence analysis of glial fibrillary acidic protein
(GFAP, astrocytes) expression in culture 7 days post-selection. (C) Total nuclei counts
immediately post-selection (Day 0) continuing 3 and 5 days post-selection. Total nuclei
number was normalized to Day 0. * indicates p < 0.05 for selected group compared to
control group. Scale bars = 100 µM.

To test for expression of functional neurotransmitter receptors we exposed cells
to selective agonists for AMPA/kainate, NMDA, glycine, and GABA receptors, all of
which activated inward current while holding cells at a fixed potential of -80 mV (Figure
4.12A). To evaluate the permeation properties of channels that underlie these responses,
we applied the agonists while ramping the membrane potential from -100 to +100 mV
(Figure 4.12B). As expected for inhibitory chloride-selective channels the currents
evoked by glycine and GABA reversed polarity near -50 mV, which is close to the
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calculated equilibrium potential for chloride during these recordings (-54 mV). In
contrast, the currents evoked by excitatory glutamate receptor agonists kainate and
NMDA reversed polarity near 0 mV, consistent with activation of non-selective cation
channels (Traynelis et al., 2010). Figure 4.12C plots the mean amplitude of agonistactivated currents recorded 0, 2, 4 and 6d after puromycin selection showing that
responses increased as differentiation proceeded. Over this same time period whole-cell
capacitance, which is proportional to surface area, increased from 22.6 ± 1.5 pF at d0
(n=11) to a plateau of 54.1 ± 2.7 pF between d5 and d8 (n=52). Taken together, our
physiological data are largely in agreement with previous work on motoneurons derived
from in vitro differentiation of mouse (Miles et al., 2004) and human (Takazawa et al.,
2012) ES cells, and with studies of primary motoneurons in dissociated culture
(Carrascal et al., 2005).

4.5 Discussion
ES cells provide an important tool that allows the study of a variety of cell types
in culture that may be difficult to isolate from primary tissue. Obtaining high purity ES
cell-derived populations, however, can be difficult due to the heterogeneity in cultures
obtained following current differentiation protocols. The MYH6 promoter has been
previously used to drive puromycin resistance in ES cell-derived cardiomyocytes leading
to significant enrichment (91.5 ± 4.3% purity) following selection (Anderson et al.,
2007). We have recently used homologous recombination at the Olig2 locus to confer
puromycin resistance and isolate pMNs from differentiated ES cell cultures (McCreedy
et al., 2012). While promising, these studies have failed to produce near pure cultures
100

Figure 4.9 Action potentials and voltage-gated whole-cell currents. (A) Sub- and suprathreshold voltage responses recorded under current clamp with 50 msec square pulse current
injections (30 and 34 pA); examples of action potential firing patterns in 3 different cells
stimulated with 800 msec square pulse current injections (K-glucuronate internal solution, d7
after selection). (B) Voltage-gated sodium channel currents evoked by steps from -60 to +12
mV from a holding potential of -80 mV; (below) Current-voltage relation for peak inward
currents. (TEA-chloride internal solution, d5 after selection). (C) Transient and sustained
voltage-gated potassium channel currents evoked by steps from -100 to +60 mV from
holding potentials of -80 and/or -40 mV. (left) Transient currents revealed by subtracting noninactivating currents evoked while holding at -40 mV from the combined currents evoked
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Figure 4.9 continued while holding at -80 mV; d4 after selection. (right) Currents evoked in
the absence and presence of 4-aminopyridine (5 mM) from a holding potential of -80, d6 after
selection. Transient currents revealed by subtracting non-inactivating currents evoked in the
presence of 4-AP from the combined currents evoked in control external solution. Currentvoltage relations for peak outward transient (filled circles) and steady state (open circles)
currents. (K-glucuronate internal solution). (D) Current mediated by voltage-gated calcium
channels evoked by steps from -100 to +90 mV from a holding potential of -80 mV. (top left)
Currents in TEA-chloride with 25 mM BaCl2 as the charge carrier, (bottom left) with addition
of the calcium channel antagonist CdCl2 (2 mM). (right) Current-voltage relation for peak
inward currents in the absence (open circles) and presence (filled circles) of cadmium. (TEAchloride internal solution, d8 after selection).

(>99%) of a single cell type. The identification of two unique enhancers of the
motoneurons associated gene Hb9, or MNX1 in the human genome, has allowed for
specific labeling of motoneurons within the mouse spinal cord (Nakano et al., 2005).
Furthermore, a 3.6 kb region including these enhancers has been used to drive GFP
expression in ES cell-derived motoneurons for FACS (Singh Roy et al., 2005). To
determine if these enhancers could drive puromycin resistance in motoneurons, we
created a selection vector with the Hb9 enhancers driving expression of the puromycin
resistance enzyme, PAC.
Transgenic mouse ES cells, generated by electroporation of a linearized Hb9Puro selection vector, maintained normal motoneuron differentiation with Hb9 mRNA
only detected following the 2-/4+ RA and Shh induction protocol. The Shh antagonist,
Cyc inhibited any detectable expression of Hb9 by PCR. Viable cells were only observed
agonist, SAG. These data indicate that expression of PAC correlates with Hb9
expression as expected. Furthermore, the two Hb9 enhancers in tandem were
sufficient, along with the minimal β-globin promoter, to provide puromycin resistance.
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The highly conserved nature of these enhancers suggests that the Hb9-Puro selection
vector may be appropriate for ES cells from other species including human ES cells.
In motoneurons development, Olig2 expression precedes the expression of
Hb9. Following commitment to the motoneurons fate, Hb9 is up-regulated as Olig2 is
down-regulated. In selected cultures, no Olig2 expression was observed. The absence
of Olig2+ cells demonstrates the appropriate temporal regulation of the Hb9-Puro
selection vector. Selected cultures stained positive for other appropriate markers for
immature neurons including β-tubulin class III (β-tubIII) and MAP-2. These results
demonstrate that expression of PAC by the Hb9-Puro selection vector is temporally and
spatially restricted to cells committed to the motoneuron fate and can be used to
generate high purity (>99%) cultures.
In studies focused on isolating motoneurons from heterogeneous cell
populations, the extended culture of motoneurons beyond 2 days while maintaining
purity has yet to be demonstrated (Gingras et al., 2007, Wada et al., 2009).
Furthermore, the maturation of motoneurons in the absence of astrocyte feeder layers is
limited. In the current study, greater than 99% of the cells in selected cultures stained
positive for the neuronal marker NF at the end of the extended cultures (up to 5 days).
Selected motoneurons were able to mature while neuronal purity was maintained at 5
days post-selection. High purity cultures also labeled with the AChE assay,
demonstrating appropriate enzymatic activity. AChE is found in any neuronal sub-type
capable of receiving cholinergic input and is not specific to motoneurons. ChAT
provides a more specific marker for motoneurons. While ChAT immunolabeling was
observed with two different antibodies, counting was not possible due to non-specific
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Figure 4.10 Action potential properties in selected motoneurons. (A) Histogram of firing
pattern as a function of days after selection. Cells spiking was classified as Single, Adapting or
Multiple for 800 msec square pulse stimulation as illustrated in Figure 4.9. (B) Number of
action potentials increased more steeply with injected current for cells in the Multiple spike
category. (C) Peak amplitude declined more gradually with spike number in the Multiple spike
category. (D) Both Adapting and Multiple spike cells displayed spike frequency adaptation,
but Adapting cells fired at lower frequency (10-15 Hz) on average than Multiple spiking cells
(20-25 Hz). (E) Phase plots (dV/dt versus Vm) for 800 msec square pulse stimulation voltage
responses of the Single spike, Adapting and Multiple spike cells shown in Figure 4.9. Firing
threshold was determined from the phase plot inflection point of the first spike.
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staining in control cultures. The poor performance of ChAT antibodies for in vitro
labeling of motoneurons has been previously reported (Bohl et al., 2008). In selected
cultures, large cells bodies with prominent neurite branching were observed almost
exclusively. Labeled neurons in control cultures were less uniform and appeared to
mature at a slower rate, possibly due to factors secreted by undesired cell types or
neuron-glia interactions. To our knowledge, this is the first study to demonstrated high
purity mature motoneurons cultures without the need of astrocytes feeder layers.
The functional properties of ES cell-derived motoneurons cultured on mouse
myotubes have been previously investigated (Miles et al., 2004). To determine if
isolated motoneurons maintain similar electrophysiological properties, we performed
whole-cell patch-clamp recordings during maturation of selected motoneurons. High
purity motoneurons displayed transient sodium and potassium currents, as well as
sustained potassium and calcium currents. Both inward sodium and outward transient
potassium currents could by inactivated by pre-pulse steps. Increasing currents were
observed during maturation of motoneurons in response to agonists for ligand-gate ion
channels. Furthermore, selected motoneurons were able to fire multiple action
potentials. These results demonstrate that isolated motoneurons maintain functional
properties. Integration of the Hb9-Puro vector into the mouse genome and subsequent
puromycin selection did not appear to hinder appropriate development of selected
motoneurons.
In this study we demonstrate that Hb9-driven puromycin resistance can be used
as a simple method for purification of ES cell-derived motoneurons. The resulting
population maintains the characteristics of ES cell-derived motoneurons and embryonic
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Figure 4.11 Steady-state inactivation of voltage-gated sodium and transient potassium
channel currents. (A) Whole-cell currents (control minus TTX) evoked by a step to 0 mV
following 60 msec pre-pulses from -100 to +10 mV. (Cs-glucuronate internal solution, d5
after selection). (right) Current-voltage relations for sodium current steady-state inactivation
(grey circles) for this cell and for activation (open circles) for the cell in Figure 4.9. Smooth
curves are best-fit Boltzmann functions for activation G = 1 / (1 + exp[-(V – Vh)/k]), where
V is the step potential in mV, Vh = -31.7 mV is the voltage for half-maximal activation and k
= 3.1 is the slope factor in mV; and, for inactivation G = 1 / (1 + exp[(V – Vh)/k]), where
Vh = -52.1 mV and k = 7.4 mV. (B) Whole-cell currents (control minus 4-AP) evoked by a
step to 0 mV following 60 msec pre-pulses from -120 to +10 mV (K-glucuronate internal
solution, d7 after selection). (right) Current-voltage relations for steady-state inactivation (grey
circles) for this cell and for activation of steady-state (open circles) and peak transient (black
circles) outward current for the cell in Figure 4.9. Smooth curves are best-fit Boltzmann
functions for inactivation G = 1 / (1 + exp[(V – Vh)/k]), where V is the step potential in
mV, Vh = -58.8 mV is the voltage for half-maximal
106 inactivation and k = 11.1 is the slope
factor in mV; and, for activation G = 1 / (1 + exp[-(V – Vh)/k]), Vh = -18.3 mV, k = 13.4
mV for transient current and Vh = 13.5 mV, k = 20.7 mV for steady-state current.

spinal motoneurons. This technique may be applied to other systems were yield is low
including human ES cell-derived motoneurons, induced pluripotent stem cell-derived
motoneurons, and direct conversion of fibroblasts in motoneurons. Further, similar
strategies can be applied to other neuronal sub-types with known unique promoters.
The resulting near pure population of cells can provide a uniform and consistent
platform for drug screening and for the study of motoneuron disease such as
amyotrophic lateral sclerosis.
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Figure 4.12 Whole-cell currents activated by excitatory and inhibitory agonists. (A) Open
boxes indicate periods of exposure to 100 µM kainate (K), NMDA (N, plus 1 µM glycine),
glycine (Gly) and GABA (K-glucuronate internal solution, 4d after selection). (B) Current
voltage relations for agonist-activated whole-cell currents as membrane potential was ramped
from -100 to +100 mV at 1.2 mV/msec. Lines plot the current recorded during agonist
exposure minus current in control extracellular solution. Note that currents evoked by
inhibitory agonists Gly (teal) and GABA (blue) reverse polarity near -47 mV, consistent with
chloride selective channels, whereas the excitatory agonists K (red) and N (gold) reverse near
0mV, as expected for cation selective channels. (Cs-glucuronate internal solution, d4 after
selection). (C) Agonist-activated currents increase with time after puromycin selection (n = 7
to 19 cells per time point).
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Table 4.1 Physiological Parameters

parameter
peak current
peak Vm
activation V1/2
slope
inactivation V1/2
slope

maximal conductance
activation V1/2
slope
inactivation V1/2
slope

Sodium
Current
-2.25 ± 0.17 nA (77)
-26.6 ± 0.8 mV (77)
-33.6 ± 1.4 mV (13)
2.7 ± 0.4 mV (13)
-41.9 ± 1.4 mV (38)
7.6 ± 0.4 mV (38)

Calcium
Currents (14)
-453.7 ± 69.5 pA
-20.7 ± 2.5 mV
-26.3 ± 1.6 mV
3.5 ± 0.6 mV
N.D.
N.D.

Potassium Currents (8)
transient
sustained
13.7 ± 2.7 pS
19.2 ± 3.1 pS
-15.5 ± 5.6 mV
11.3 ± 2.5 mV
12.3 ± 1.8 mV
20.6 ± 0.9 mV
-56.0 ± 1.8 mV
N.D.
10.4 ± 0.4 mV
N.D.
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Chapter 5
Summary and Future Direction
5.1 Summary of Findings
The overall goal of this thesis was to develop new tools for stem cell-based
therapies, in particular, cell-replacement strategies following spinal cord injury (SCI).
Appropriate cell types for replacement must be identified experimentally, requiring large
populations of relatively pure cell types. Differentiation of embryonic stem (ES) cells
typically results in a heterogeneous population of cells. Included in this mixed
population are pluripotent ES cells that can lead to tumor formation following
transplantation into the CNS (Erdo et al., 2003). Techniques to purify specific cell-types
are needed to realize the full utility of transplant populations. The generation of two
high purity cell populations, progenitor motor neurons (pMNs) and post-mitotic
motoneurons, was accomplished in this thesis. In addition, the differentiated of high
purity progenitor motoneurons was assessed following encapsulation in tissue
engineered fibrin scaffolds in vitro and when transplantation into the injured spinal cord.
In Chapter 2, high purity progenitor motor neuron cell populations were
generated and characterized using the genetically engineered mouse ES cell line, POlig2. Expression of the puromycin resistance enzyme, puromycin N-acetyltransferase
(PAC), was accomplished by homologous recombination at the Olig2 locus. PAC
expression under the Olig2 gene regulatory elements provided puromycin resistance in
pMNs. Puromycin exposure during differentiation of P-Olig2 ES cells killed all cells not
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expressing Olig2, resulting in enrichment of Olig2+ pMNs. Due to the rapid
differentiation of pMNs into post-mitotic motoneurons, the latter population was also
enriched. Enriched pMNs differentiated into appropriate cells types including
oligodendrocytes and motoneurons. The results of chapter two demonstrate that
transgenic enrichment provides a powerful tool for generating high-purity neural subtype populations.
The ability of high-purity pMNs to survive and differentiate when encapsulated
within tissue engineered fibrin scaffolds in vitro and following transplantation into the
injured spinal cord was assessed in Chapter 3. Delivery of growth factors was
accomplished using a heparin-binding delivery system (HBDS) cross-linked within
fibrin scaffolds. Growth factor presence resulted in small changes in differentiation of
control pMN populations and enriched pMN populations compared to the same cell
population in fibrin scaffolds alone. When the growth factor combination
NT3+GDNF was delivered with the HBDS, significant enhancement of
oligodendrocyte differentiation in enriched pMN populations compared to control
pMN populations was observed. Enriched pMNs survived following transplantation
into the sub-acute SCI. Growth factors did not effect cell survival as previously seen
with heterogeneous ESNPCs. This may be due to removal of undesired pluripotent ES
cells by puromycin selection or differences in the two populations used (pMNs vs.
ESNPCs). Enriched pMNs differentiated into the appropriate cell types in the injured
cord, including cholinergic motoneurons. Transgenic enrichment of pMN transplant
populations appears to be a viable platform for ES cell-based therapies in SCI.
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In Chapter 4, the ability to generate high purity neuronal populations, in
particular post-mitotic motoneurons, via transgenic expression of PAC was developed
and characterized. A new transgenic mouse ES cell line was developed by random
incorporation of a vector containing two small enhancer elements of the motoneuron
gene Hb9 preceding the minimal β-globin promoter and the PAC gene. Puromycin
resistance was specific to post-mitotic motoneurons. High-purity populations of
immature post-mitotic motoneurons were obtained. Purity was maintained through
maturation and uniform populations of cholinergic motoneurons developed. Mitotic
glial populations were not observed at any time point as assessed by proliferation assays
and immunofluorescence. High purity motoneurons were electrophysiologically active
and expressed appropriate ion channels. This technique provides an inexpensive and
more effective method for generating high purity ES-cell derived motoneurons.
Overall the research presented in this thesis demonstrates that antibiotic
selection is a reasonable mechanism for generating homogeneous ES cell-derived neural
populations. Progenitor and terminally differentiated cell types can be obtained.
Following antibiotic selection, isolated cell types behave similar to their in vivo
counterparts. These cell populations may have therapeutic potential for treating CNS
disorders including SCI. Antibiotic selection may advance many studies in
developmental biology and provide a uniform platform for toxicology screening.

5.2 Recommendations for Future Directions
The work presented in this thesis focused on the development and
characterization of high purity neural cell populations. While pMNs and post-mitotic
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motoneurons were obtained in these studies, it may be feasible to obtain other cell types
and neurons with therapeutic potential including dopaminergic neurons,
oligodendrocytes, and spinal interneurons. Antibiotic selection required genomic
modification to express the puromycin resistance enzyme. Mouse ES cells were
genetically engineered prior to differentiation and needed several weeks to expand in
culture. This time scale can be greatly expanded when working with human ES cells.
Methods for integration free expression can eliminate the risks associated with
transgenic modification and may allow for selection of unmodified cells during
differentiation. This technology could facilitate the use of autologous stem cells
including iPSCs.
The highly enriched populations of pMNs were evaluated for their ability to
survive and differentiation in a short term model of SCI transplantation. To fully
determine the tumor forming potential, long term studies are needed. Assessing the
long term effect on SCI can elucidate the ability of these cell types to integrate and
promote functional recovery and repair. Combining high purity pMNs with other
strategies for SCI repair could produce synergistic improvements. Removing undesired
cell types can eliminate common complications associated with ES cell-based therapies.
Increasing safety can also promote translation into other CNS disorders including
amyotrophic lateral sclerosis, Parkinson’s disease, and stroke.

5.2.1 Long-term SCI Studies
We have demonstrated short term survival, differentiation and migration of
transplanted high purity pMNs within a sub-acute rodent SCI model. The lack of over113

proliferation by transplanted cells in the presence of growth factors suggests that tumor
forming cells have been eliminated by antibiotic selection. Indeed pluripotent ES cells
are removed during selection of pMNs with puromycin. However, to fully demonstrate
the safety of enriched pMN cell populations, a long term transplantation study is
needed. Control unselected cultures should be transplanted to demonstrate that the
tumor forming potential previously seen with heterogeneous ESNPC transplant
populations is also present in heterogeneous pMN cultures. In addition to
tumorgenicity, the ability for high purity ES cell-derived pMNs to integrate into the
injured spinal cords can also be assessed at later time points. Behavioral benefit can be
demonstrated by the BBB locomotor test and complemented with the grid walk step
test. Von Frey hair test should be combined with functional motor tests to determine if
pMN transplantation leads to allodynia as commonly observed with NSCs (Hofstetter et
al., 2005, Macias et al., 2006).

5.2.2 Other Potential Cell Types
ES cells have been used to generate many different cell types from all three
germ layers (Williams et al., 2012). Apoptotic death of oligodendrocytes has been
shown following SCI leading to demyelination of spared axonal pathways (Crowe et al.,
1997). Many protocols have been developed to enrich ES cell-derived populations for
oligodendrocytes (Liu et al., 2000, Sharp et al., 2011). High purity differentiation of
mouse and human ES cells has been demonstrated, however, this may depend on the
cell line used and cannot guarantee removal of pluripotent embryonic stem cells that fail
to differentiate. Development of oligodendrocytes and motoneurons depends on early
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expression of Olig2 as both cell types arise from Olig2-expressiong pMNs (Dessaud et
al., 2008). However, Olig2 expression is maintained in oligodendrocytes and peaks in a
late phase of oligodendrocyte development. Puromycin selection at this later stage may
lead to high purity oligodendrocyte populations with known therapeutic potential in
both SCI and multiple sclerosis repair.
Parkinson’s disease (PD) is a neurodegenerative disorder marked by loss of
dopaminergic neurons in the substantia nigra (Bjorklund et al., 2002). Symptoms of PD
include tremors and motor rigidity. ES cell-derived dopaminergic neurons have been
shown to alleviate symptoms of PD in animal models (Roy et al., 2006, Yang et al.,
2008). Transplantation of ES cells into the human brain carries significant safety risks
and represents a significant hurdle in clinical translation. Tyrosine hydroxylase has been
used to drive GFP expression in dopaminergic neurons (Donaldson et al., 2005).
Tyrosine hydroxylase may be useful in driving puromycin resistance with subsequent
purification. This technique may provide high purity dopaminergic neurons with great
ease and enhance the potential of PD cell replacement therapies.
The role of spinal interneurons in relaying descending motor signals around the
injury site has been demonstrated in multiple studies (Murray and Goldberger, 1974,
Bareyre et al., 2004, Rosenzweig et al., 2010). Differentiation of ventral spinal
interneurons follows a similar pattern to motoneurons. Small populations of ventral
interneurons have been demonstrated during differentiation of mouse ES cells into
motoneurons (Wichterle et al., 2002, Harper et al., 2004). However, the low rate of
occurrence of these cell types limits their use in therapeutic applications. Isolating
spinal interneurons by antibiotic selection may prove as a critical step in the
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development of studies involving spinal interneurons including cell replacement
therapies and developmental studies.

5.2.3 Safe Integration or Integration Free
Random incorporation of the PAC vector can lead to gene disruption with
catastrophic consequences. Placing these vectors in safe harbor sites for integration,
such as the Rosa26 locus in mice or the AAV locus in humans can prevent these
complications (Perez-Pinera et al., 2012). Recent advances in zing finger integration
technology has allowed for genomic insertion at these sites in an efficient manner
without the need for homologous recombination. Fully utilization of antibiotic
selection may rely on proper integration or methods that do not require genomic
modification.
Recent technological developments for deriving iPSCs from somatic cell types
have led to integration free gene expression (Bayart and Cohen-Haguenauer, 2013).
Avoiding integration can eliminate the need to clone and expand cells with identified
integration events. Potential disruption of important gene expression can also be
eliminated. Adding vectors that allow for expression of PAC under control of the Hb9
transcription factor can promote puromycin resistance in developing motoneurons
during the directed differentiation of ES cells. With this technology, puromycin
resistance can be driven in motoneurons differentiated from any stem cell line allowing
for quick and effective purification of motoneurons.
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5.2.4 Combination Therapies with High Purity pMNs
While the high purity pMN transplants encapsulated in tissue engineered fibrin
scaffolds represent a combination therapy in itself, addition factors may improve the
benefit of the total therapy. In particular, methods to overcome CSPG inhibition and
myelin-associated inhibition could drastically improve the benefit of pMN transplants.
CSPGs can be degraded by inject or sustained delivery of chondroitinase ABC
(ChABC), a bacterial enzyme that degrades CSPG glycosaminoglycan inhibitory side
chains (Yamagata et al., 1968, Bradbury et al., 2002). ChABC administration has also
been shown to improve cell migrated from transplanted cellular grafts (Hwang et al.,
2011). Degrading CSPGs may allow better integration into host tissue by reducing
inhibition at the transplant-host interface and promoting axon extension from
transplanted pMNs differentiating into neurons. Myelin-associated inhibition can be
reduced by the peptide competitive agonist NEP1-40 (GrandPre et al., 2000). Blocking
axon inhibition by myelin debris and myelin present in the white matter may improve
axon extension from transplanted cells while improving migration into host tissue.
Combining ChABC and NEP1-40 together could maximize the potential therapeutic
benefit from pMN transplantation.

5.2.5 High Purity Motoneurons in Amyotrophic Lateral Sclerosis
In CNS disorders where extensive tissue damage is not observed, such as
amyotrophic lateral sclerosis (ALS), transplantation volumes must be minimalized to
prevent transplant associated damage. In spinal cord this is particularly important, as
even small injuries can have catastrophic implications. Unlike SCI, only motoneurons
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undergo cell death, suggesting that high purity motoneuron transplants would be most
effective in restoring function. Transplantation of heterogeneous ES cell-derived
motoneuron cultures have been shown to extend out into peripheral nerves in rodent
models of spinal motoneuron disease (Deshpande et al., 2006). Survival of transplanted
cells into the uninjured spinal cord is significantly greater compared to the injured spinal
cord. Transplantation in amyotrophic lateral sclerosis therefore, may be easier to
accomplish. However, if survival of high purity transplanted MNs is poor in rodent
models of spinal motoneuron loss, the addition of growth factors or a non-hydrolizable
form cyclic adenosine monophosphate (cAMP) may enhance survival. High purity
pMN and motoneuron ES cell-derived populations represent a promising platform for
cell replacement therapies in CNS disease and disorders.
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Appendix A
Matlab Code for Immunohistochemical Analysis of
Injured Spinal Cords in Chapter 3
SCIanalyzer*.m – Quantative Analysis of green fluorescent protein (GFP), DAPI,
and differentiation markers. * = differentiation marker
clc
clear
files = dir('*.tif');
dirSize = numel(files);
fileMatrix = {files.name};
gfpSearch = regexp(fileMatrix,'GFP');
stainSearch = regexp(fileMatrix, '*'); % * = differentiation marker (Btub, ChAT, NeuN, O4,
GFAP, nestin)
dapiSearch = regexp (fileMatrix, 'Hoe');
gfpSearch = ~cellfun('isempty', gfpSearch);
stainSearch = ~cellfun('isempty', stainSearch);
dapiSearch = ~cellfun('isempty', dapiSearch);
l=1;
for k = 1:dirSize
if gfpSearch(k) == 1
gfpMatrix(:,:,l)= imread(files(k).name);
l=l+1;
end
end
l=1;
for k = 1:dirSize
if stainSearch(k) == 1
stainMatrix(:,:,l)= imread(files(k).name);
l=l+1;
end
end
l=1;
for k = 1:dirSize
if dapiSearch(k) == 1
dapiMatrix(:,:,l)= imread(files(k).name);
l=l+1;
end
end
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dirSplit = dirSize/3;
for p = 1:dirSplit
gfpFile = gfpMatrix(:,:,p);
stainFile = stainMatrix(:,:,p);
dapiFile = dapiMatrix(:,:,p);
%threshold of image and convert to binary black and white
threshedGfp = 0.15;
bwGfp = im2bw(gfpFile, threshedGfp);
threshedStain = 0.14;
bwStain = im2bw(stainFile, threshedStain);
threshedDapi = 0.135;
bwDapi = im2bw(dapiFile, threshedDapi);
clusterSize = 250;
cellArea = cellSize(bwDapi, clusterSize);
for j = 1:length(bwGfp)
for i = 1:(numel(bwGfp)/length(bwGfp))
if bwGfp(i,j)> 0
bwStain(i,j)= bwStain(i,j);
bwDapi(i,j)= bwDapi(i,j);
else
bwStain(i,j)= 0;
bwDapi(i,j)= 0;
end
end
end
dapiCount = cellCount(bwDapi, clusterSize, cellArea);
gfpPix=find(bwGfp);
gfpCount=size(gfpPix);
gfpCount=gfpCount(1);
stainPix=find(bwStain);
stainCount=size(stainPix);
stainCount=stainCount(1);
DataMatrix(:,p) = {cellArea gfpCount stainCount dapiCount};
end

cellSize.m– Function to determine average nuclei size for nuclei counting
function meanCellArea = cellSize(fileName, clusterSize)
[dapiFile, dapiNum]= bwlabel(fileName, 4);
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dapiStats = regionprops(dapiFile, 'Area');
dapiArea = [dapiStats.Area];
idx = find (dapiArea <clusterSize & dapiArea > 25);
no_outliers = ismember (dapiFile, idx);
[smallCells, numSmallCells] = bwlabel(no_outliers, 4);
dapiStatsSmall = regionprops (smallCells, 'Area');
dapiAreaSmall = [dapiStatsSmall.Area];
meanCellArea = mean (dapiAreaSmall);

cellCount.m– Function to count number of cells in an image
function [DapiCount] = cellCount(fileName, clusterSize, cellArea)
[dapiFile, dapiNum]= bwlabel(fileName, 4);
dapiStats = regionprops(dapiFile, 'Area');
dapiArea = [dapiStats.Area];
idx = find (dapiArea <clusterSize & dapiArea > 25);
no_outliers = ismember (dapiFile, idx);
[smallCells, numSmallCells] = bwlabel(no_outliers, 4);
idx2 = find (dapiArea > clusterSize);
outliers = ismember (dapiFile, idx2);
[bigCells, numBigCells] = bwlabel(outliers);
dapiStatsBig = regionprops (bigCells, 'Area');
dapiAreaBig = [dapiStatsBig.Area];
numOutlyingCells = round (dapiAreaBig/cellArea);
DapiCount = sum([numSmallCells numOutlyingCells]);
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